Catherine M. Sherwin

Catherine M. Sherwin, PhD, BSc (Hons), BN, MSCI

Languages spoken: English

Academic Information

Departments Adjunct - Pediatrics

Divisions: Clinical Pharmacology

Board Certification

  • American Board of Clinical Pharmacology

Research Interests

  • Clinical Pediatric Pharmacology and Toxicology
  • Pharmacokinetics
  • Pharmacodynamics
  • Pharmacogenomics
  • Modeling and Simulation (Pharmacometrics)
  • Clinical Trial Simulation
  • Optimal Trial Design
  • Therapeutics
  • Toxicology
  • Personalized Medicine

Dr. Catherine Sherwin, a Professor, and Vice‐chair for Research at the Department of Pediatrics, Wright State University Boonshoft School of Medicine and Dayton Children's Hospital. Dr. Sherwin was formerly an Associate Professor, Chief of the Division of Clinical Pharmacology and Director of the Utah Pediatric Clinical Pharmacology Fellowship Program, Department of Pediatrics, University of Utah School of Medicine. She still holds an Adjunct position in the Department of Pharmacotherapy, College of Pharmacy, Univeraoiut of Utah. She earned her Ph.D. at the University of Otago, Dunedin School of Medicine, New Zealand in Paediatric Clinical Pharmacology in 2007. She then completed one year of postdoctoral training in

the Women’s and Children’s Health in Dunedin and then a two‐year NIH T32 Fellowship training program in the Divisions of Clinical Pharmacology and Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center. She received board certification from the American Board of Clinical Pharmacology in 2011. Dr. Sherwin became a Fellow (FCP) of the Americal College of Clinical Pharmacology (ACCP) in 2014 and was voted to the Board of Regents for ACCP in 2018.

Dr. Sherwin has expertise and experience in the development of quantitative pharmacometric (PK/PD/PG) models in special populations, including pediatric and neonatal patients. Dr. Sherwin’s areas of clinical research focus are clinical pharmacology/toxicology and pharmacometrics within the area of pediatrics and maternal health, and specifically the juncture of the two: neonatology and pregnancy. She is highly committed to understanding how the physical size and physiological based information can be systematically utilized to understand the

inherent pharmacology. She has a combination of skill sets that are in high demand; having been trained in pediatric clinical pharmacology and pharmacometrics. The natural overlap between these two areas of expertise complement one another and allow Dr. Sherwin to provide a unique level of technical depth and research insight to pediatric studies. Her research involves understanding the pharmacology of drugs in neonatal and pediatric populations which has allowed her to become an expert in the techniques of pharmacometric modeling and scaling which are crucial for pediatric clinical trials. Dr. Sherwin’s research has a highly clinical focus and combines the utility and innovation of modeling and simulation to provide research answers to real clinical questions. Dr. Sherwin’s research and expertise are also in optimal sample design and clinical trial simulation. Dr. Sherwin has specific interests and expertise with numerous drug classes including antibiotics, immunosuppressants, antiepileptics, anesthetic agents and opioids.

Research Statement

Dr. Catherine Sherwin is currently an Associate Professor and Chief of the Division of Clinical Pharmacology, Department of Pediatrics, University of Utah School of Medicine. She earned her PhD at the University of Otago, Dunedin School of Medicine, New Zealand in Paediatric Clinical Pharmacology in 2007. She then completed one year of Postdoctoral training in the Women’s and Children’s Health in Dunedin and then a two year T32 Fellowship training program in the Divisions of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center. She received board certification from the American Board of Clinical Pharmacology in 2011. Dr. Sherwin has expertise and experience in the development of quantitative pharmacometric (PK/PD/PG) models in special populations including pediatric and neonatal patients.

Dr. Sherwin’s areas of clinical research focus are clinical pharmacology/toxicology and pharmacometrics within the area of pediatrics and maternal health, and specifically the juncture of the two: neonatology and pregnancy. She is highly committed to understanding how physical size and physiological based information can be systematically utilized understand the inherent pharmacology. She has a combination of skill sets that are in high demand; having been trained in pediatric clinical pharmacology and pharmacometrics. The natural overlap between these two areas of expertise complement one another and allow Dr. Sherwin to provide a unique level of technical depth and research insight to pediatric studies. Dr. Sherwin’s research has a highly clinical focus and combines the utility and innovation of modeling and simulation to provide research answers to real clinical questions.

Education History

Graduate Training University of Utah
 MSc
Cincinnati Children's Hospital Medical Center, Divisions of Clinical Pharmacology and Rheumatology
 Postdoctoral Clinical Research Fellow
Postdoctoral Fellowship University of Otago, Dunedin School of Medicine, Department of Women’s and Children’s Health
 Postdoctoral Clinical Research Fellow
University of Otago, Dunedin School of Medicine, Department of Women’s and Children’s Health
 PhD
Other Training Otago School of Medicine and Health Sciences, Department Pharmacology & Toxicology
Christchurch School of Medicine and Health Sciences, Canterbury Health Laboratory
Undergraduate Lincoln University and Research performed at Agri-Quality Animal Health Laboratory
 BS
Certification Meadowbank TAFE College, Concord General Repatriation Hospital
 Certificate

Selected Publications

Journal Article

  1. Rahimi R, Heidari-Soureshjani S, Sherwin CMT, Kasiri K, Rahimian G (2024). The Association between Gallstone Disease and Incidence of Cardiovascular Disease: A Systematic Review and Meta-Analysis. Rev Recent Clin Trials. (Read full article)
  2. Chhibber A, Watanabe AH, Jacobs H, Kharat A, Syeed SM, Sherwin CM, Chaiyakunapruk N, Biskupiak J, Yellepeddi VK, Brixner D, Young DC (2024). Potential of pharmacogenetics in minimizing drug therapy problems in cystic fibrosis. J Cyst Fibros, 23(5), 1010-1019. (Read full article)
  3. Maglalang PD, Sinha J, Zimmerman K, McCann S, Edginton A, Hornik CP, Hornik CD, Muller WJ, Al-Uzri A, Meyer M, Chen JY, Anand R, Perrin EM, Gonzalez D, Delmore P, Dixit S, Shimizu J, Shakespear K, Salman Y, Rosen P, Perez R, Narus JA, Alger F, Sherwin C, Spigarelli M, Talbert J, Mariconti A, Bernhardt J, Laughon M, Wiseheart M, Perry J, Michael A, Comings J, Brown K, Konow C, Poff S, Kernen K, Sullivan J, Ann DP, Howard L, Hart M, Hansberry D, James L, Parsons A, Petersen L, Tasi C, Adams R, Goldblatt E, Vitou B, Lemon E, Speicher D, Toltzis P, Borges A, Thoma K, Rathore M, Rumantir M, Finkelstein Y, Lang E, Shankar K, Deville J, Moore A, Kost B, Sokol G, Poindexter B, Denne S, Baez A, Wrenn S, Milleson C, Tiedge H, Baisden N, Jefferson G, Watt K, Kirby C, Gerhardt B, DePaoli B, Arnold P, Terrell T, Mottes T, Goldstein S, Bradley G, Ieradi S, Murchison B, Tuttle A, Pohl D, Lacaze T, Zemek R, McMillan H, Van K, Steinbeiss M, Sierra Y, Rutebemberwa A, Ralston K, Malone K, Halstenson G, Dix M, DiDomenico D, Deschenes J, Mourani P, Goldenberg N, Lague V (2024). Application of Physiologically Based Pharmacokinetic Modeling to Characterize the Effects of Age and Obesity on the Disposition of Levetiracetam in the Pediatric Population. Clin Pharmacokinet, 63(6), 885-899. (Read full article)
  4. Holford N, OHanlon CJ, Allegaert K, Anderson B, Falco A, Simon N, Lo YL, Thomson AH, Sherwin CM, Jacqz-Aigrain E, Llanos-Paez C, Hennig S, Mockus L, Kirkpatrick C (2024). A physiological approach to renal clearance: From premature neonates to adults. Br J Clin Pharmacol, 90(4), 1066-1080. (Read full article)
  5. Wu Y, Allegaert K, Flint RB, Goulooze SC, Vlitalo PAJ, de Hoog M, Mulla H, Sherwin CMT, Simons SHP, Krekels EHJ, Knibbe CAJ, Vller S (2024). When will the Glomerular Filtration Rate in Former Preterm Neonates Catch up with Their Term Peers? Pharm Res, 41(4), 637-649. (Read full article)
  6. Han X, Vollmer D, Yan X, Zhang Y, Zang M, Zhang C, Sherwin CM, Enioutina EY (2024). Immunomodulatory Effects of Modified Colostrum, Whey, and Their Combination With Other Natural Products: Effects on Natural Killer Cells. Curr Ther Res Clin Exp, 101. (Read full article)
  7. Emami E, Sherwin CMT, Heidari-Soureshjani S (2024). Effect of Probiotics on Urinary Tract Infections in Children: A Systematic Review and Meta-Analysis. Curr Rev Clin Exp Pharmacol, 19(1), 111-121. (Read full article)
  8. Ghahfarrokhi SH, Heidari-Soureshjani S, Sherwin CMT, Azadegan-Dehkordi Z (2023). Efficacy and Mechanisms of Silybum Marianum, Silymarin, and Silibinin on Rheumatoid Arthritis and Osteoarthritis Symptoms: A Systematic Review. Curr Rheumatol Rev, 20(4), 414-425. (Read full article)
  9. Jivad N, Heidari-Soureshjani S, Bagheri H, Sherwin CMT, Rostamian S (2023). Anti-seizure Effects and Mechanisms of Berberine: A Systematic Review. Curr Pharm Biotechnol, 25(17), 2253-2265. (Read full article)
  10. Khaghani A, Kasiri K, Heidari-Soureshjani S, Sherwin CMT, Mardani-Nafchi H (2024). A Systematic Review and Meta-analysis of the Relationship between Statin Intake and Esophageal Cancer. Anticancer Agents Med Chem, 24(14), 1029-1037. (Read full article)
  11. Rahimi-Dehkordi N, Heidari-Soureshjani S, Sherwin CMT (2024). The Effects and Safety of Silymarin on β-thalassemia in Children and Adolescents: A Systematic Review based on Clinical Trial Studies. Rev Recent Clin Trials, 19(4), 242-255. (Read full article)
  12. Rahimi R, Masoumi S, Badali A, Jafari N, Heidari-Soureshjani S, Sherwin CMT (2024). Association Between Gallstone Disease and Risk of Mortality of Cardiovascular Disease and Cancer: A Systematic Review and Meta-Analysis. Cardiovasc Hematol Disord Drug Targets, 24(1), 47-58. (Read full article)
  13. Haslund-Krog S, Barry JM, Birnbaum AK, Dalhoff K, Brink Henriksen T, Sherwin CMT, Avachat C, Poulsen S, Christensen U, Remmel RP, Wilkins D, van den Anker JN, Holst H (2023). Pharmacokinetics and safety of prolonged paracetamol treatment in neonates: An interventional cohort study. Br J Clin Pharmacol, 89(11), 3421-3431. (Read full article)
  14. Fike CD, Aschner JL, Avachat C, Birnbaum AK, Sherwin CMT (2023). Multi-dose enteral L-citrulline administration in premature infants at risk of developing pulmonary hypertension associated with bronchopulmonary dysplasia. J Perinatol. (Read full article)
  15. Krepkova LV, Babenko AN, Lemyaseva SV, Saybel OL, Sherwin CM, Enioutina EY (2023). Modulation of Hepatic Functions by Chicory (Cichorium intybus L.) Extract: Preclinical Study in Rats. Pharmaceuticals (Basel), 16(10). (Read full article)
  16. Krepkova LV, Babenko AN, Lemyaseva SV, Saybel OL, Sherwin CM, Enioutina EY (2023). Modulation of Hepatic Functions by Chicory (Cichorium intybus L.) Extract: Preclinical Study in Rats †. Pharmaceuticals (Basel), 16(10). (Read full article)
  17. Zhang T, Smit C, Sherwin CMT, Knibbe CAJ, Krekels EHJ (2023). Vancomycin Clearance in Obese Adults is not Predictive of Clearance in Obese Adolescents. Clin Pharmacokinet. (Read full article)
  18. Emami E, Heidari-Soureshjani S, Oroojeni Mohammadjavad A, Sherwin CM (2022). Obesity and the Risk of Developing Kidney Stones: A Systematic Review and Meta-analysis. Iran J Kidney Dis, 1(2), 63-72. (Read full article)
  19. Oyebanji OA, Brewer C, Bayless S, Schmeusser B, Corbin DA, Sulentic CEW, Sherwin CMT, Chen Y, Rapp CM, Cates EE, Long Y, Travers JB, Rohan CA (2023). Topical photodynamic therapy generates bioactive microvesicle particles: evidence for a novel pathway involved in immunosuppressive effects. J Invest Dermatol. (Read full article)
  20. Zhang T, Smit C, Sherwin CMT, Knibbe CAJ, Krekels EHJ (2023). Vancomycin Clearance in Obese Adults is not Predictive of Clearance in Obese Adolescents. Clin Pharmacokinet. (Read full article)
  21. Mohammadi-Dashtaki R, Heidari-Soureshjani S, Sherwin CMT (2023). The Effect of Inhalation Aromatherapy on Patients with Cardiovascular Disease Seeking Pain Relief: A Systematic Review and Meta-analysis. Curr Drug ther, 18(3), 262-270. (Read full article)
  22. Fike CD, Aschner JL, Avachat C, Birnbaum AK, Sherwin CMT (2023). Multi-dose enteral L-citrulline administration in premature infants at risk of developing pulmonary hypertension associated with bronchopulmonary dysplasia. J Perinatol. (Read full article)
  23. Savadjani SA, Sherwin CM, Heidari-Soureshjani S, Darvishi M, Amiri MM (2022). The Role of Vitamin D in Carpal Tunnel Syndrome Risk and Supplementation Outcomes: A Systematic Review. Curr Rheumatol Rev, 19(4), 439-448. (Read full article)
  24. Rostamian S, Heidari-Soureshjani S, Sherwin CMT (2023). The Therapeutic Effect of Silymarin and Silibinin on Depression and Anxiety Disorders and Possible Mechanism in the Brain: A Systematic Review. Cent Nerv Syst Agents Med Chem, 23(2), 86-94. (Read full article)
  25. Emami E, Heidari-Soureshjani S, Sherwin CM (2021). Anti-inflammatory response to curcumin supplementation in chronic kidney disease and hemodialysis patients: A systematic review and meta-analysis. Avicenna J Phytomed, 12(6), 576-588. (Read full article)
  26. Fike CD, Avachat C, Birnbaum AK, Aschner JL, Sherwin CM (2022). Pharmacokinetics of L-Citrulline in Neonates at Risk of Developing Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension. Paediatr Drugs. (Read full article)
  27. Sherwin CM, Tran NK, Sullivan K, Wead S, Birnbaum AK, Avachat C, Kagan RJ, Healy DP (2022). Exploring the past to inform the future to optimize the pharmacokinetics of vancomycin in children with severe burn injuries. J Burn Care Res. (Read full article)
  28. Derbalah A, Duffull S, Sherwin CM, Job K, Al-Sallami H (2022). Optimal dosing of enoxaparin in overweight and obese children. Br J Clin Pharmacol. (Read full article)
  29. Gerhart JG, Carreo FO, Ford JL, Edginton A, Perrin EM, Watt KM, Muller WJ, Atz AM, Al-Uzri A, Delmore P, Gonzalez D, Benjamin DK, Hornik C, Zimmerman K, Kennel P, Beci R, Dang Hornik C, Kearns GL, Laughon M, Paul IM, Sullivan J, Wade K, Delmore P, Taylor-Zapata P, Lee J, Anand R, Sharma G, Simone G, Kaneshige K, Taylor L, Al-Uzri A, Hornik C, Sokol G, Speicher D, Sullivan J, Mourani P, Mendley S, Meyer M, Atkins R, Flynn J, Vaughns J, Sherwin C, Delmore P, Goldstein S, Rathore M, Melloni C, Muller W, Delmore P, Tremoulet A, James L, Mendley S, Blackford M, Atz A, Adu-Darko M, Mourani P, Watt K, Hornik C, Al-Uzri A, Sullivan J, Laughon M, Brian Smith P, Watt K, Cheifetz I, Atz A, Bhatt-Mehta V, Fernandez A, Lowry J (2022). Use of physiologically-based pharmacokinetic modeling to inform dosing of the opioid analgesics fentanyl and methadone in children with obesity. CPT Pharmacometrics Syst Pharmacol, 11(6), 778-791. (Read full article)
  30. McKnite AM, Job KM, Nelson R, Sherwin CMT, Watt KM, Brewer SC (2022). Medication based machine learning to identify subpopulations of pediatric hemodialysis patients in an electronic health record database. Inform Med Unlocked, 34. (Read full article)
  31. McGlone CL, Christian L, Schmeusser B, Liu L, Chalfant CE, Stephensen DJ, Sherwin CM, Rapp CM, Sattouf Z, Rohan CA, Morris C, Chen Y, Travers JB (2021). Evidence for Systemic Reactive Oxygen Species in UVB-mediated Microvesicle Formation. Photochem Photobiol, 98(1), 242-247. (Read full article)
  32. McKnite AM, Job KM, Nelson R, Sherwin CMT, Watt KM, Brewer SC (2022). Medication based machine learning to identify subpopulations of pediatric hemodialysis patients in an electronic health record database. Inform Med Unlocked, 34. (Read full article)
  33. Maharaj AR, Wu H, Zimmerman KO, Muller WJ, Sullivan JE, Sherwin CMT, Autmizguine J, Rathore MH, Hornik CD, Al-Uzri A, Payne EH, Benjamin DK Jr, Hornik CP, Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee (2021). Pharmacokinetics of Ceftazidime in Children and Adolescents with Obesity. Paediatr Drugs, 23(5), 499-513. (Read full article)
  34. Barry JM, Birnbaum AK, Jasin LR, Sherwin CM (2021). Maternal Exposure and Neonatal Effects of Drugs of Abuse. J Clin Pharmacol, 61 Suppl 2, S142-S155. (Read full article)
  35. Krepkova LV, Bortnikova VV, Babenko AN, Mizina PG, Mkhitarov VA, Job KM, Sherwin CM, Enioutina EY (2021). Effects of a new thyrotropic drug isolated from Potentilla alba on the male reproductive system of rats and offspring development. BMC Complement Med Ther, 21(1), 31. (Read full article)
  36. Heidari-Soureshjani S, Sherwin CMT (2021). Effects of medicinal plants on human hosts and zoonotic helminthic infections: A systematic review. Nat Prod J, 11(4), 472-490. (Read full article)
  37. Biltaji E, Enioutina EY, Yellepeddi V, Rower JE, Sherwin CMT, Ward RM, Lemons RS, Constance JE (2020). Supportive care medications coinciding with chemotherapy among children with hematologic malignancy. Leuk Lymphoma, 61, 1-12. (Read full article)
  38. Kumar SS, Liu X, Sherwin CM, Jones BL (2020). The Reliability of Histamine Pharmacodynamic Response Phenotype Classification in Children With Allergic Disease. Front Pharmacol, 11. (Read full article)
  39. Kumar SS, Liu X, Sherwin CM, Jones BL (2020). The Reliability of Histamine Pharmacodynamic Response Phenotype Classification in Children With Allergic Disease. Front Pharmacol, 11, 227. (Read full article)
  40. Rashid J, Kumar SS, Job KM, Liu X, Fike CD, Sherwin CMT (2020). Therapeutic Potential of Citrulline as an Arginine Supplement: A Clinical Pharmacology Review. Paediatr Drugs, 22(3), 279-293. (Read full article)
  41. Illamola SM, Amaeze OU, Krepkova LV, Birnbaum AK, Karanam A, Job KM, Bortnikova VV, Sherwin CMT, Enioutina EY (2020). Use of Herbal Medicine by Pregnant Women: What Physicians Need to Know. Front Pharmacol, 10, 1483. (Read full article)
  42. Kamp J, Olofsen E, Henthorn TK, Van Velzen M, Niesters M, Dahan A, Backman JT, Drover DR, Elkomy MH, Fanta S, Flint RB, Gustafsson LL, Hammer GB, Herd DW, Kalso E, Matht RAA, Olkkola K, Peltoniemi M, Persson J, Ramamoorthy C, Saari TI, Sherwin CMT (2020). Ketamine Pharmacokinetics: A Systematic Review of the Literature, Meta-analysis, and Population Analysis. Anesthesiology, 1192-1213. (Read full article)
  43. Tak CR, Kim J, Gunning K, Sherwin CM, Nickman NA, Biskupiak JE (2019). Cost-Sharing Requirements for the Herpes Zoster Vaccine in Adults Aged 60+. J Pharm Technol, 35(6), 258-269. (Read full article)
  44. Wang H, Sherwin C, Gobburu JVS, Ivaturi V (2019). Population Pharmacokinetic Modeling of Gentamicin in Pediatrics. J Clin Pharmacol, 59(12), 1584-1596. (Read full article)
  45. Radhakrishnan SV, Boyer M, Sherwin CM, Zangari M, Tricot G (2019). A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma. Cell Transplant, 28(12), 1624-1631. (Read full article)
  46. Tak CR, Kim J, Gunning K, Sherwin CM, Nickman NA, Biskupiak JE (2019). Cost-Sharing Requirements for the Herpes Zoster Vaccine in Adults Aged 60. J Pharm Technol, 35(6), 258-269. (Read full article)
  47. Balch A, Wilkes J, Thorell E, Pavia A, Sherwin CMT, Enioutina EY (2019). Changing trends in IVIG use in pediatric patients: A retrospective review of practices in a network of major USA pediatric hospitals. Int Immunopharmacol, 76, 105868. (Read full article)
  48. Thyagarajan A, Alshehri MSA, Miller KLR, Sherwin CM, Travers JB, Sahu RP (2019). Myeloid-Derived Suppressor Cells and Pancreatic Cancer: Implications in Novel Therapeutic Approaches. Cancers (Basel), 11(11). (Read full article)
  49. Wagstaff JS, Durrant RJ, Newman MG, Eason R, Ward RM, Sherwin CMT, Enioutina EY (2019). Antibiotic Treatment of Suspected and Confirmed Neonatal Sepsis Within 28 Days of Birth: A Retrospective Analysis. Front Pharmacol, 10, 1191. (Read full article)
  50. Deng J, Chalhoub NE, Sherwin CM, Li C, Brunner HI (2019). Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum, 49(2), 251-259. (Read full article)
  51. Wang J, Kumar SS, Sherwin CM, Ward R, Baer G, Burckart GJ, Wang Y, Yao LP (2019). Renal Clearance in Newborns and Infants: Predictive Performance of Population-Based Modeling for Drug Development. Clin Pharmacol Ther, 105(6), 1462-1470. (Read full article)
  52. Krzyzanski W, Cook SF, Wilbaux M, Sherwin CMT, Allegaert K, Vermeulen A, van den Anker JN (2019). Population Pharmacokinetic Modeling in the Presence of Missing Time-Dependent Covariates: Impact of Body Weight on Pharmacokinetics of Paracetamol in Neonates. AAPS J, 21(4), 68. (Read full article)
  53. Tak CR, Biltaji E, Kohlmann W, Maese L, Hainaut P, Villani A, Malkin D, Sherwin CMT, Brixner DI, Schiffman JD (2019). Cost-effectiveness of early cancer surveillance for patients with Li-Fraumeni syndrome. Pediatr Blood Cancer, 66(5), e27629. (Read full article)
  54. Rower JE, Anderson DJ, Sherwin CM, Reilly CA, Ballard PL, McEvoy CT, Wilkins DG (2019). Development and validation of an assay for quantifying budesonide in dried blood spots collected from extremely low gestational age neonates. J Pharm Biomed Anal, 167, 7-14. (Read full article)
  55. Liu X, Smits A, Wang Y, Renard M, Wead S, Kagan RJ, Healy DP, De Cock P, Allegaert K, Sherwin CMT (2018). Impact of Disease on Amikacin Pharmacokinetics and Dosing in Children. Ther Drug Monit, 41(1), 44-52. (Read full article)
  56. Stockmann C, Olson J, Rashid J, Lubsch L, Young DC, Hersh AL, Frymoyer A, Ampofo K, Liu X, Wang Y, Sherwin CMT, Zobell JT (2018). An Evaluation of Vancomycin Area Under the Curve Estimation Methods for Children Treated for Acute Pulmonary Exacerbations of Cystic Fibrosis Due to Methicillin-Resistant Staphylococcus aureus. J Clin Pharmacol, 59(2), 198-205. (Read full article)
  57. Tak CR, Gunning K, Kim J, Sherwin CM, Ruble JH, Nickman NA, Biskupiak JE (2018). The effect of a prescription order requirement for pharmacist-administered vaccination on herpes zoster vaccination rates. Vaccine, 37(4), 631-636. (Read full article)
  58. Wagstaff JS, Durrant RJ, Newman MG, Eason R, Ward RM, Sherwin CMT, Enioutina EY (2019). Antibiotic treatment of suspected and confirmed neonatal sepsis within 28 days of birth: A retrospective analysis. Front Pharmacol, 10. (Read full article)
  59. Illamola SM, Amaeze OU, Krepkova LV, Birnbaum AK, Karanam A, Job KM, Bortnikova VV, Sherwin CMT, Enioutina EY (2019). Use of herbal medicine by pregnant women: What physicians need to know. Front Pharmacol, 10. (Read full article)
  60. Yellepeddi V, Rower J, Liu X, Kumar S, Rashid J, Sherwin CMT (2018). State-of-the-Art Review on Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development. Clin Pharmacokinet, 58(1), 1-13. (Read full article)
  61. Becker SM, Job KM, Lima K, Forbes TJ, Wagstaff J, Tran NK, Sherwin CM, Nelson DS, Johnson MD, Rower JE (2018). Prospective study of serum and ionized magnesium pharmacokinetics in the treatment of children with severe acute asthma. Eur J Clin Pharmacol, 75(1), 59-66. (Read full article)
  62. Grimsrud KN, Ivanova X, Sherwin CM, Palmieri TL, Tran NK (2018). Identification of Cytochrome P450 Polymorphisms in Burn Patients and Impact on Fentanyl Pharmacokinetics: A Pilot Study. J Burn Care Res, 40(1), 91-96. (Read full article)
  63. Ananthula HK, Parker S, Touchette E, Buller RM, Patel G, Kalman D, Salzer JS, Gallardo-Romero N, Olson V, Damon IK, Moir-Savitz T, Sallans L, Werner MH, Sherwin CM, Desai PB (2018). Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents. BMC Pharmacol Toxicol, 19(1), 80. (Read full article)
  64. Linakis MW, Cook SF, Kumar SS, Liu X, Wilkins DG, Gaedigk R, Gaedigk A, Sherwin CMT, van den Anker JN (2018). Polymorphic Expression of UGT1A9 is Associated with Variable Acetaminophen Glucuronidation in Neonates: A Population Pharmacokinetic and Pharmacogenetic Study. Clin Pharmacokinet, 57(10), 1325-1336. (Read full article)
  65. Illamola SM, Sherwin CM, van Hasselt JGC (2018). Clinical Pharmacokinetics of Amikacin in Pediatric Patients: A Comprehensive Review of Population Pharmacokinetic Analyses. Clin Pharmacokinet, 57(10), 1217-1228. (Read full article)
  66. Illamola SM, Huynh HQ, Liu X, Bhakta ZN, Sherwin CM, Liou TG, Carveth H, Young DC (2018). Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis. Antimicrob Agents Chemother, 62(10). (Read full article)
  67. Linakis MW, Cook SF, Kumar SS, Liu X, Wilkins DG, Gaedigk R, Gaedigk A, Sherwin CM, van den Anker JN (2018). Polymorphic Expression of UGT1A9 is Associated with Variable Acetaminophen Glucuronidation in Neonates: A Population Pharmacokinetic and Pharmacogenetic Study. Clin Pharmacokinet.
  68. Illamola SM, Bucci-Rechtweg C, Costantine MM, Tsilou E, Sherwin CM, Zajicek A (2018). Inclusion of pregnant and breastfeeding women in research - efforts and initiatives. Br J Clin Pharmacol, 84(2), 215-222. (Read full article)
  69. Ward RM, Benjamin DK Jr, Davis JM, Gorman RL, Kauffman R, Kearns GL, Murphy MD, Sherwin CMT (2017). The Need for Pediatric Drug Development. J Pediatr, 192, 13-21. (Read full article)
  70. Ward RM, Benjamin DK Jr, Davis JM, Gorman RL, Kauffman R, Kearns GL, Murphy MD, Sherwin CM (2018). The Need for Pediatric Drug Development. J Pediatr, 192, 13-21.
  71. Rower JE, Stockmann C, Linakis MW, Kumar SS, Liu X, Kent Korgenski E, Sherwin CMT, Molina KM (2017). Predicting tacrolimus concentrations in children receiving a heart transplant using a population pharmacokinetic model. BMJ Paediatr Open, 1(1). (Read full article)
  72. Linakis MW, Rower JE, Roberts JK, Miller EI, Wilkins DG, Sherwin CMT (2017). Population pharmacokinetic model of transdermal nicotine delivered from a matrix-type patch. Br J Clin Pharmacol, 83(12), 2709-2717. (Read full article)
  73. Enioutina EY, Teng L, Fateeva TV, Brown JCS, Job KM, Bortnikova VV, Krepkova LV, Gubarev MI, Sherwin CMT (2017). Phytotherapy as an alternative to conventional antimicrobials: combating microbial resistance. Expert Rev Clin Pharmacol, 10(11), 1203-1214. (Read full article)
  74. Constance JE, Reith D, Ward RM, Balch A, Stockmann C, Korgenski EK, Thorell EA, Sherwin CMT (2017). Risk of nonsteroidal anti-inflammatory drug-associated renal dysfunction among neonates diagnosed with patent ductus arteriosus and treated with gentamicin. J Perinatol, 37(10), 1093-1102. (Read full article)
  75. Tak CR, Job KM, Schoen-Gentry K, Campbell SC, Carroll P, Costantine M, Brixner D, Birnbaum AK, Sherwin CMT (2017). The impact of exposure to antidepressant medications during pregnancy on neonatal outcomes: a review of retrospective database cohort studies. Eur J Clin Pharmacol, 73(9), 1055-1069. (Read full article)
  76. Linakis MW, Job KM, Liu X, Collingwood SC, Pangburn HA, Ott DK, Sherwin CMT (2017). Riding (High) into the danger zone: a review of potential differences in chemical exposures in fighter pilots resulting from high altitude and G-forces. Expert Opin Drug Metab Toxicol, 13(9), 925-934. (Read full article)
  77. Linakis MW, Rower JE, Roberts JK, Miller EI, Wilkins DG, Sherwin CM (2017). Population Pharmacokinetic Model of Transdermal Nicotine Delivered from a Matrix-Type Patch. Br J Clin Pharmacol, 83(12), 2709-2717.
  78. Constance JE, Campbell SC, Somani AA, Yellepeddi V, Owens KH, Sherwin CMT (2017). Pharmacokinetics, pharmacodynamics and pharmacogenetics associated with nonsteroidal anti-inflammatory drugs and opioids in pediatric cancer patients. Expert Opin Drug Metab Toxicol, 13(7), 715-724. (Read full article)
  79. Constance JE, Reith D, Ward RM, Balch A, Stockmann C, Korgenski EK, Thorell EA, Sherwin CM (6/8/2017). Risk of nonsteroidal anti-inflammatory drug-associated renal dysfunction among neonates diagnosed with patent ductus arteriosus and treated with gentamicin. J Perinatol, (Jun 8).
  80. Constance JE, Campbell SC, Somani AA, Yellepeddi V, Owens KH, Sherwin CM (6/1/2017). Pharmacokinetics, Pharmacodynamics and Pharmacogenetics associated with Nonsteroidal Anti-Inflammatory Drugs and Opioids in Pediatric Cancer Patients. Expert Opin Drug Metab Toxicol, (Jun 5), 1-10.
  81. Enioutina EY, Salis ER, Job KM, Gubarev MI, Krepkova LV, Sherwin CM (2017). Herbal Medicines: challenges in the modern world. Part 5. status and current directions of complementary and alternative herbal medicine worldwide. Expert Rev Clin Pharmacol, 10(3), 327-338. (Read full article)
  82. Rower JE, Liu X, Yu T, Mundorff M, Sherwin CM, Johnson MD (2017). Clinical pharmacokinetics of magnesium sulfate in the treatment of children with severe acute asthma. Eur J Clin Pharmacol, 73(3), 325-331. (Read full article)
  83. Yu T, Enioutina EY, Brunner HI, Vinks AA, Sherwin CM (2017). Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus. Clin Pharmacokinet, 56(2), 107-125. (Read full article)
  84. Jones BL, Sherwin CMT, Liu X, Dai H, Vyhlidal CA (2017). Genetic variation in the histamine production, response, and degradation pathway is associated with histamine pharmacodynamic response in children with asthma. Front Pharmacol, 7(JAN). (Read full article)
  85. Jones BL, Sherwin CM, Liu X, Dai H, Vyhlidal CA (2016). Genetic Variation in the Histamine Production, Response, and Degradation Pathway Is Associated with Histamine Pharmacodynamic Response in Children with Asthma. Front Pharmacol, 7, 524. (Read full article)
  86. Rower JE, Stockmann C, Linakis MW, Kumar SS, Liu X, Korgenski EK, Sherwin CMT, Molina KM (2017). Predicting tacrolimus concentrations in children receiving a heart transplant using a population pharmacokinetic model. BMJ Paediatr Open, 1, e000147. (Read full article)
  87. Lanke S, Yu T, Rower JE, Balch AH, Korgenski EK, Sherwin CM (2017). AUC-Guided Vancomycin Dosing in Adolescent Patients With Suspected Sepsis. J Clin Pharmacol, 57(1), 77-84. (Read full article)
  88. Rower JE, Stockmann C, Linakis MW, Kumar SS, Liu X, Korgenski EK, Sherwin CM, Molina KM (2017). Predicting Tacrolimus Concentrations in Children Receiving a Heart Transplant Using a Population Pharmacokinetic Model. BMJ Paediatr Open, 1(e000147).
  89. Burch PT, Spigarelli MG, Lambert LM, Loftus PD, Sherwin CM, Linakis MW, Sheng X, LuAnn Minich L, Williams RV (2016). Use of Oxandrolone to Promote Growth in Neonates following Surgery for Complex Congenital Heart Disease: An Open-Label Pilot Trial. Congenit Heart Dis, 11(6), 693-699. (Read full article)
  90. Liu X, Yu T, Rower JE, Campbell SC, Sherwin CM, Johnson MD (2016). Optimizing the use of intravenous magnesium sulfate for acute asthma treatment in children. Pediatr Pulmonol, 51(12), 1414-1421. (Read full article)
  91. Job KM, Kiang TK, Constance JE, Sherwin CM, Enioutina EY (2016). Herbal medicines: challenges in the modern world. Part 4. Canada and United States. Expert Rev Clin Pharmacol, 9(12), 1597-1609. (Read full article)
  92. Cook SF, Stockmann C, Samiee-Zafarghandy S, King AD, Deutsch N, Williams EF, Wilkins DG, Sherwin CM, van den Anker JN (2016). Neonatal Maturation of Paracetamol (Acetaminophen) Glucuronidation, Sulfation, and Oxidation Based on a Parent-Metabolite Population Pharmacokinetic Model. Clin Pharmacokinet, 55(11), 1395-1411. (Read full article)
  93. Janssen EJ, Valitalo PA, Allegaert K, de Cock RF, Simons SH, Sherwin CM, Mouton J, van den Anker JN, Knibbe CA (2016). Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling. Antimicrob Agents Chemother, 60(2), 1031-21.
  94. Teng L, Zu Q, Li G, Yu T, Job KM, Yang X, Di L, Sherwin CM, Enioutina EY (2016). Herbal medicines: challenges in the modern world. Part 3. China and Japan. Expert Rev Clin Pharmacol, 9(9), 1225-33. (Read full article)
  95. Dobson NR, Liu X, Rhein LM, Darnall RA, Corwin MJ, McEntire BL, Ward RM, James LP, Sherwin CM, Heeren TC, Hunt CE (2016). Salivary caffeine concentrations are comparable to plasma concentrations in preterm infants receiving extended caffeine therapy. Br J Clin Pharmacol, 82(3), 754-61. (Read full article)
  96. Sammons HM, Gubarev MI, Krepkova LV, Bortnikova VV, Corrick F, Job KM, Sherwin CM, Enioutina EY (2016). Herbal medicines: challenges in the modern world. Part 2. European Union and Russia. Expert Rev Clin Pharmacol, 9(8), 1117-27. (Read full article)
  97. Liu X, Jones BL, Roberts JK, Sherwin CM (2016). Population pharmacokinetic/pharmacodynamic modeling of histamine response measured by histamine iontophoresis laser Doppler. J Pharmacokinet Pharmacodyn, 43(4), 385-93. (Read full article)
  98. Job KM, Olson J, Stockmann C, Constance JE, Enioutina EY, Rower JE, Linakis MW, Balch AH, Yu T, Liu X, Thorell EA, Sherwin CM (2016). Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections. Expert Rev Anti Infect Ther, 14(8), 731-46. (Read full article)
  99. Campbell SC, Kast TT, Kamyar M, Robertson J, Sherwin CM (2016). Calls to a teratogen information service regarding potential exposures in pregnancy and breastfeeding. BMC Pharmacol Toxicol, 17(1), 33. (Read full article)
  100. Tak CR, Yu T, Sherwin CMT, Mihalopoulos NL (2016). Optimizing enrollment in pediatric obese patients: reflections on recruitment characteristics. Int J Adolesc Med Health, 29(6). (Read full article)
  101. Tak C, Yu T, Sherwin CM, Mihalopoulos NL (2016). Optimizing enrollment in pediatric obese patients: reflections on recruitment characteristics. Int J Adolesc Med Health, 29(6).
  102. Barnes J, McLachlan AJ, Sherwin CM, Enioutina EY (2016). Herbal medicines: challenges in the modern world. Part 1. Australia and New Zealand. Expert Rev Clin Pharmacol, 9(7), 905-15. (Read full article)
  103. Yu T, Balch AH, Ward RM, Korgenski EK, Sherwin CM (2016). Incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates. BMC Pharmacol Toxicol, 17(1), 22. (Read full article)
  104. Stockmann C, Sammons H, Starkey E, Constance JE, Sherwin CM (2016). Unanswered Questions Regarding Optimal Pediatric Vancomycin Use. Ther Drug Monit, 38(3), 419-20. (Read full article)
  105. Constance JE, Balch AH, Stockmann C, Linakis MW, Korgenski EK, Roberts JK, Ward RM, Sherwin CM, Spigarelli MG (2015). A propensity-matched cohort study of vancomycin-associated nephrotoxicity in neonates. Arch Dis Child Fetal Neonatal Ed, 101(3), F236-43. (Read full article)
  106. Yu T, Campbell SC, Stockmann C, Tak C, Schoen K, Clark EA, Varner MW, Spigarelli MG, Sherwin CM (2016). Pregnancy-induced changes in the pharmacokinetics of caffeine and its metabolites. J Clin Pharmacol, 56(5), 590-6. (Read full article)
  107. Bhongsatiern J, Stockmann C, Yu T, Constance JE, Moorthy G, Spigarelli MG, Desai PB, Sherwin CM (2016). Renal Function Descriptors in Neonates: Which Creatinine-Based Formula Best Describes Vancomycin Clearance? J Clin Pharmacol, 56(5), 528-40. (Read full article)
  108. Stockmann C, Sammons H, Starkey E, Constance JE, Sherwin CM (2016). Unanswered questions regarding optimal pediatric vancomycin use. Ther Drug Monit, Apr 14.
  109. Linakis MW, Roberts JK, Lala AC, Spigarelli MG, Medlicott NJ, Reith DM, Ward RM, Sherwin CM (2016). Challenges Associated with Route of Administration in Neonatal Drug Delivery. Clin Pharmacokinet, 55(2), 185-96. (Read full article)
  110. Cook SF, Roberts JK, Samiee-Zafarghandy S, Stockmann C, King AD, Deutsch N, Williams EF, Allegaert K, Wilkins DG, Sherwin CM, van den Anker JN (2016). Population Pharmacokinetics of Intravenous Paracetamol (Acetaminophen) in Preterm and Term Neonates: Model Development and External Evaluation. Clin Pharmacokinet, 55(1), 107-19. (Read full article)
  111. Janssen EJ, Vlitalo PA, Allegaert K, de Cock RF, Simons SH, Sherwin CM, Mouton JW, van den Anker JN, Knibbe CA (2016). Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling. Antimicrob Agents Chemother, 60(2), 1013-21. (Read full article)
  112. Roberts JK, Stockmann C, Ward RM, Beachy J, Baserga MC, Spigarelli MG, Sherwin CM (2015). Population Pharmacokinetics of Darbepoetin Alfa in Conjunction with Hypothermia for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy. Clin Pharmacokinet, 54(12), 1237-44. (Read full article)
  113. Bhongsatiern J, Stockmann C, Roberts JK, Yu T, Korgenski KE, Spigarelli MG, Desai PB, Sherwin CM (2015). Evaluation of Vancomycin Use in Late-Onset Neonatal Sepsis Using the Area Under the Concentration-Time Curve to the Minimum Inhibitory Concentration ≥400 Target. Ther Drug Monit, 37(6), 756-65. (Read full article)
  114. Stockmann C, Barrett JS, Roberts JK, Sherwin CM (2015). Use of Modeling and Simulation in the Design and Conduct of Pediatric Clinical Trials and the Optimization of Individualized Dosing Regimens. CPT Pharmacometrics Syst Pharmacol, 4(11), 630-40.
  115. Stockmann C, Barrett JS, Roberts JK, Sherwin CMT (2015). Use of modeling and simulation in the design and conduct of pediatric clinical trials and the optimization of individualized dosing regimens. CPT Pharmacometrics Syst Pharmacol, 4(11), 630-640. (Read full article)
  116. Stockmann C, Barrett JS, Roberts JK, Sherwin C (2015). Use of Modeling and Simulation in the Design and Conduct of Pediatric Clinical Trials and the Optimization of Individualized Dosing Regimens. CPT Pharmacometrics Syst Pharmacol, 4(11), 630-40. (Read full article)
  117. Roberts JK, Cook SF, Stockmann C, Rollins DE, Wilkins DG, Sherwin CM (2015). A Population Pharmacokinetic Analysis of Dextroamphetamine in the Plasma and Hair of Healthy Adults. Clin Drug Investig, 35(10), 633-43. (Read full article)
  118. Constance JE, Balch AH, Stockmann C, Linakis MW, Korgenski EK, Roberts JK, Ward RM, Sherwin CM, Spigarelli MG (2015). A propensity-matched cohort study of vancomycin-associated nephrotoxicity in neonates. Arch Dis Child Fetal Neonatal Ed, Sep 23.
  119. Stockmann C, Spigarelli MG, Healy DP, Gottschlich MM, Kagan R, Balch AH, Sherwin C (2015). Application of a method used to deconstruct a single dose pharmacokinetic profile from multiple dose data. Biopharm Drug Dispos, 36(6), 405-409. (Read full article)
  120. Stockmann C, Spigarelli MG, Healy DP, Gottschlich MM, Kagan R, Balch AH, Sherwin C (2015). Application of a method used to deconstruct a single dose pharmacokinetic profile from multiple dose data. Biopharm Drug Dispos, 36(6), 405-409. (Read full article)
  121. Baserga MC, Beachy JC, Roberts JK, Ward RM, DiGeronimo RJ, Walsh WF, Ohls RK, Anderson J, Mayock DE, Juul SE, Christensen RD, Loertscher MC, Stockmann C, Sherwin CM, Spigarelli MG, Yoder BA (2015). Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial. Pediatr Res, 78(3), 315-22. (Read full article)
  122. Linakis MW, Stockmann C, Campbell SC, Williams RV, Burch PT, Lambert LM, Sherwin CM, Reilly CA, Spigarelli MG (2015). Quantitative Assay Validation for Oxandrolone in Human Plasma Using LC-MS-MS. J Anal Toxicol, 39(7), 526-31. (Read full article)
  123. Baserga MC, Beachy JC, Roberts JK, Ward RM, DiGeronimo RJ, Walsh WF, Ohls RK, Anderson J, Mayock DE, Juul SE, Christensen RD, Loertscher MC, Stockmann C, Sherwin CM, Spigarelli MG, Yoder BA (2015). Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial. Pediatr Res, 78(3), 315-22.
  124. Yu T, Stockmann C, Healy DP, Olson J, Wead S, Neely AN, Kagan RJ, Spigarelli MG, Sherwin CM (2015). Determination of Optimal Amikacin Dosing Regimens for Pediatric Patients With Burn Wound Sepsis. J Burn Care Res, 36(4), e244-52. (Read full article)
  125. Stockmann C, Hersh AL, Roberts JK, Bhongsatiern J, Korgenski EK, Spigarelli MG, Sherwin CMT, Frymoyer A (2015). Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates. Infect Dis Ther, 4(2), 187-198. (Read full article)
  126. Stockmann C, Ampofo K, Pavia AT, Byington CL, Blaschke AJ, Sherwin CM, Spigarelli MG, Hersh AL (2015). National trends in the incidence, outcomes and charges of pediatric osteoarticular infections, 1997-2012. Pediatr Infect Dis J, 34(6), 672-4. (Read full article)
  127. Stockmann C, Hersh AL, Roberts JK, Bhongsatiern J, Korgenski EK, Spigarelli MG, Sherwin CM, Frymoyer A (2015). Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates. Infect Dis Ther, 4(2), 187-98. (Read full article)
  128. Lala AC, Broadbent RS, Medlicott NJ, Sherwin CM, Reith DM (2014). Illustrative neonatal cases regarding drug delivery issues. J Paediatr Child Health, 51(5), 478-481. (Read full article)
  129. Stockmann C, Roberts JK, Yellepeddi VK, Sherwin CM (2015). Clinical pharmacokinetics of inhaled antimicrobials. Clin Pharmacokinet, 54(5), 473-92. (Read full article)
  130. Roberts JK, Stockmann C, Balch A, Yu T, Ward RM, Spigarelli MG, Sherwin CM (2015). Optimal design in pediatric pharmacokinetic and pharmacodynamic clinical studies. Paediatr Anaesth, 25(3), 222-30. (Read full article)
  131. Sherwin CM, Stockmann C, Grimsrud K, Herd DW, Anderson BJ, Spigarelli MG (2015). Development of an optimal sampling schedule for children receiving ketamine for short-term procedural sedation and analgesia. Paediatr Anaesth, 25(2), 211-6. (Read full article)
  132. Ward RM, Sherwin CM (2015). Ethics of drug studies in the newborn. Paediatr Drugs, 17(1), 37-42. (Read full article)
  133. Balch AH, Constance JE, Thorell EA, Stockmann C, Korgenski EK, Campbell SC, Spigarelli MG, Sherwin CM (2015). Pediatric vancomycin dosing: Trends over time and the impact of therapeutic drug monitoring. J Clin Pharmacol, 55(2), 212-20. (Read full article)
  134. Stockmann C, Hillyard B, Ampofo K, Spigarelli MG, Sherwin CM (2015). Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis. Expert Rev Respir Med, 9(1), 13-22. (Read full article)
  135. Stockmann C, Roberts JK, Knackstedt ED, Spigarelli MG, Sherwin CM (2015). Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection. Expert Opin Drug Metab Toxicol, 11(2), 205-19. (Read full article)
  136. Stockmann C, Gottschlich MM, Healy D, Khoury JC, Mayes T, Sherwin CM, Spigarelli MG, Kagan RJ (2015). Relationship between zolpidem concentrations and sleep parameters in pediatric burn patients. J Burn Care Res, 36(1), 137-44. (Read full article)
  137. Stockmann C, Spigarelli MG, Healy D, Gottschlich M, Kagan R, Balch AH, Sherwin CM (2015). Application of a method used to deconstruct a single dose pharmacokinetic profile from multiple dose data. Biopharm Drug Dispos, 12(Epub).
  138. Yang X, Sherwin CM, Yu T, Yellepeddi VK, Brunner HI, Vinks AA (2015). Pharmacokinetic modeling of therapies for systemic lupus erythematosus. Expert Rev Clin Pharmacol, 8(5), 587-603. (Read full article)
  139. Enioutina EY, Constance JE, Stockmann C, Linakis MW, Yu T, Rower JE, Balch AH, Sherwin CM (2015). Pharmacokinetic considerations in the use of antivirals in neonates. Expert Opin Drug Metab Toxicol, 11(12), 1861-78. (Read full article)
  140. Grimsrud KN, Sherwin CM, Constance JE, Tak C, Zuppa AF, Spigarelli MG, Mihalopoulos NL (2015). Special population considerations and regulatory affairs for clinical research. Clin Res Regul Aff, 32(2), 47-56. (Read full article)
  141. Yakub SY, Constance JE, Stockmann C, Linakis M, Campbell SC, Sherwin CM, Korgenski EK, Balch A, Spigarelli MG (2014). Epidemiological Evaluation of Blood Culture Patterns among Neonates Receiving Vancomycin. Indian J Microbiol, 54(4), 389-95. (Read full article)
  142. Doll E, Wilkes J, Cook LJ, Korgenski EK, Faix RG, Yoder BA, Srivastava R, Sherwin CM, Spigarelli MG, Clark EA, Bonkowsky JL (2014). Neonatal magnesium levels correlate with motor outcomes in premature infants: a long-term retrospective cohort study. Front Pediatr, 2, 120. (Read full article)
  143. Stockmann C, Roberts JK, Yu T, Constance JE, Knibbe CA, Spigarelli MG, Sherwin CM (2014). Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections. Expert Rev Anti Infect Ther, 12(11), 1371-1388.
  144. Yakub SY, Constance JE, Stockmann C, Linakis M, Campbell SC, Sherwin CM, Korgenski EK, Balch A, Spigarelli MG (2014). Epidemiological Evaluation of Blood Culture among Neonates Receiving Vancomycin. Indian J Microbiol, 54(4), 389-395.
  145. Lala AC, Broadbent RS, Medlicott NJ, Sherwin CM, Reith DM (2014). Illustrative neonatal cases regarding drug delivery issues. J Paediatr Child Health.
  146. Doll E, Wilkes J, Cook LJ, Korgenski EK, Faix RG, Yoder BA, Srivastava R, Sherwin CMT, Spigarelli MG, Clark EAS, Bonkowsky JL (2014). Neonatal magnesium levels correlate with motor outcomes in premature infants: A long-term retrospective cohort study. Front Pediatr, 2(NOV). (Read full article)
  147. Stockmann C, Roberts JK, Yu T, Constance JE, Knibbe CA, Spigarelli MG, Sherwin CM (2014). Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections. Expert Rev Anti Infect Ther, 12(11), 1371-88. (Read full article)
  148. Yakub SY, Constance JE, Stockmann C, Linakis M, Campbell SC, Sherwin CMT, Korgenski EK, Balch A, Spigarelli MG (2014). Epidemiological Evaluation of Blood Culture Patterns among Neonates Receiving Vancomycin. Indian J Microbiol, 54(4), 389-395. (Read full article)
  149. De Cock RF, Allegaert K, Brussee JM, Sherwin CM, Mulla H, de Hoog M, van den Anker JN, Danhof M, Knibbe CA (2014). Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration. Pharm Res, 31(10), 2643-54. (Read full article)
  150. Campbell SC, Stockmann C, Balch A, Clark EA, Kamyar M, Varner M, Korgenski EK, Bonkowsky JL, Spigarelli MG, Sherwin CM (2014). Intrapartum magnesium sulfate and the potential for cardiopulmonary drug-drug interactions. Ther Drug Monit, 36(4), 544-8. (Read full article)
  151. Roberts JK, Stockmann C, Constance JE, Stiers J, Spigarelli MG, Ward RM, Sherwin CM (2014). Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants. Clin Pharmacokinet, 53(7), 581-610. (Read full article)
  152. Sherwin CM, Medlicott NJ, Reith DM, Broadbent RS (2014). Intravenous drug delivery in neonates: lessons learnt. Arch Dis Child, 99(6), 590-4. (Read full article)
  153. Stockmann C, Sherwin CM, Buterbaugh W, Spigarelli MG, Gottschlich MM, Healy D, Kagan RJ (2014). Preliminary assessment of zolpidem pharmacokinetics in pediatric burn patients. Ther Drug Monit, 36(3), 295-301. (Read full article)
  154. Stockmann C, Constance JE, Roberts JK, Olson J, Doby EH, Ampofo K, Stiers J, Spigarelli MG, Sherwin CM (2014). Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications. Clin Pharmacokinet, 53(5), 429-54. (Read full article)
  155. Schoen K, Yu T, Stockmann C, Spigarelli MG, Sherwin CM (2014). Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity. Paediatr Drugs, 16(2), 169-77. (Read full article)
  156. Stockmann C, Sherwin CM, Koren G, Campbell SC, Constance JE, Linakis M, Balch A, Varner MW, Spigarelli MG (2014). Characteristics and publication patterns of obstetric studies registered in ClinicalTrials.gov. J Clin Pharmacol, 54(4), 432-7. (Read full article)
  157. Sherwin CM, Balch A, Campbell SC, Fredrickson J, Clark EA, Varner M, Stockmann C, Korgenski EK, Bonkowsky JL, Spigarelli MG (2014). Maternal magnesium sulphate exposure predicts neonatal magnesium blood concentrations. Basic Clin Pharmacol Toxicol, 114(4), 318-22. (Read full article)
  158. Sherwin CM, Wead S, Stockmann C, Healy D, Spigarelli MG, Neely A, Kagan R (2014). Amikacin population pharmacokinetics among paediatric burn patients. Burns, 40(2), 311-8. (Read full article)
  159. Stockmann C, Hersh AL, Sherwin CM, Spigarelli MG (2014). Alignment of United States funding for cardiovascular disease research with deaths, years of life lost, and hospitalizations. Int J Cardiol, 172(1), e19-21. (Read full article)
  160. Yu T, Stockmann C, Balch AH, Spigarelli MG, Sherwin CM (2014). Evolution of interventional vancomycin trials in light of new antibiotic development in the USA, 1999-2012. Int J Antimicrob Agents, 43(3), 215-22. (Read full article)
  161. De Cock RF, Allegaert K, Sherwin CM, Nielsen EI, de Hoog M, van den Anker JN, Danhof M, Knibbe CA (2014). A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates. Pharm Res, 31(3), 754-67. (Read full article)
  162. Lacher S, Gremaud J, Skagen K, Steed E, Dalton R, Sugden K, Cardozo-Pelaez F, Sherwin C, Woodahl E (2014). Absence of P-glycoprotein transport in the pharmacokinetics and toxicity of the herbicide paraquats. J Pharmacol Exp Ther, 348(2), 336-345. (Read full article)
  163. Sherwin CM, Zobell JT, Stockmann C, McCrory BE, Wisdom M, Young DC, Olson J, Ampofo K, Spigarelli MG (2014). Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis. J Pharmacokinet Pharmacodyn, 41(1), 71-9. (Read full article)
  164. Stockmann C, Sherwin CM, Ampofo K, Spigarelli MG (2014). Development of levofloxacin inhalation solution to treat Pseudomonas aeruginosa in patients with cystic fibrosis. Ther Adv Respir Dis, 8(1), 13-21. (Read full article)
  165. Lacher SE, Gremaud JN, Skagen K, Steed E, Dalton R, Sugden KD, Cardozo-Pelaez F, Sherwin CM, Woodahl EL (2014). Absence of P-glycoprotein transport in the pharmacokinetics and toxicity of the herbicide paraquat. J Pharmacol Exp Ther, 348(2), 336-45. (Read full article)
  166. Stockmann C, Spigarelli MG, Campbell SC, Constance JE, Courter JD, Thorell EA, Olson J, Sherwin CM (2014). Considerations in the pharmacologic treatment and prevention of neonatal sepsis. Paediatr Drugs, 16(1), 67-81. (Read full article)
  167. Sherwin CM, Ngamprasertwong P, Sadhasivam S, Vinks AA (2014). Utilization of optimal study design for maternal and fetal sheep propofol pharmacokinetics study: a preliminary study. Curr Clin Pharmacol, 9(1), 64-9. (Read full article)
  168. Stockmann C, Sherwin CM, Zobell JT, Lubsch L, Young DC, Olson J, Noyes BE, Ampofo K, Spigarelli MG (2013). Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis. Pharmacotherapy, 33(12), 1288-96. (Read full article)
  169. Stockmann C, Spigarelli MG, Ampofo K, Sherwin CM (2013). Bioequivalence and Bioavailability Clinical Trials: A Status Report from the National Institutes of Health ClinicalTrials.gov Registry. J Bioequivalence Bioavailab, 5, 244-247. (Read full article)
  170. Young DC, Zobell JT, Stockmann C, Waters CD, Ampofo K, Sherwin CM, Spigarelli MG (2013). Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides. Pediatr Pulmonol, 48(11), 1047-61. (Read full article)
  171. Stockmann C, Sherwin CM, Ampofo K, Hersh AL, Pavia AT, Byington CL, Ward RM, Spigarelli MG (2013). Characteristics of antimicrobial studies registered in the USA through ClinicalTrials.Gov. Int J Antimicrob Agents, 42(2), 161-6. (Read full article)
  172. Jones BL, Kearns G, Neville KA, Sherwin CM, Spigarelli MM, Leeder JS (2013). Variability of histamine pharmacodynamic response in children with allergic rhinitis. J Clin Pharmacol, 53(7), 731-7. (Read full article)
  173. Zobell JT, Young DC, Waters CD, Ampofo K, Stockmann C, Sherwin CM, Spigarelli MG (2013). Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary. Pediatr Pulmonol, 48(6), 525-37. (Read full article)
  174. Zobell JT, Young DC, Waters CD, Ampofo K, Stockmann C, Sherwin CM, Spigarelli MG (2013). Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary. Pediatr Pulmonol, 48(6), 525-37.
  175. Lambton SL, Nicol CJ, Friel M, Main DC, McKinstry JL, Sherwin CM, Walton J, Weeks CA (2013). A bespoke management package can reduce levels of injurious pecking in loose-housed laying hen flocks. Vet Rec, 172(16), 423. (Read full article)
  176. Stockmann C, Sherwin CM, Zobell JT, Young DC, Waters CD, Spigarelli MG, Ampofo K (2012). Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones. Pediatr Pulmonol, 48(3), 211-20. (Read full article)
  177. Stockmann C, Sherwin CM, Zobell JT, Young DC, Waters CD, Spigarelli MG, Ampofo K (2013). Optimization of Anti-pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations: III. Fluoroquinolones. Pediatr Pulmonol, 48(3), 211-20.
  178. Zobell JT, Waters CD, Young DC, Stockmann C, Ampofo K, Sherwin CM, Spigarelli MG (2012). Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins. Pediatr Pulmonol, 48(2), 107-22. (Read full article)
  179. Stockmann C, Spigarelli MG, Ampofo K, Sherwin CMT (2013). Bioequivalence and bioavailability clinical trials: A status report from the national institutes of health ClinicalTrials.gov registry. J Bioequivalence Bioavailab, 5(6), 244-247. (Read full article)
  180. Young DC, Zobell JT, Waters CD, Ampofo K, Stockmann C, Sherwin CM, Spigarelli MG (2012). Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. colistimethate sodium. Pediatr Pulmonol, 48(1), 1-7. (Read full article)
  181. Sherwin CM, Nasr MA, Gale E, Petek M, Stafford K, Turp M, Coles GC (2013). Prevalence of nematode infection and faecal egg counts in free-range laying hens: relations to housing and husbandry. Br Poult Sci, 54(1), 12-23. (Read full article)
  182. Young DC, Zobell JT, Waters CD, Ampofo K, Stockmann C, Sherwin CM, Spigarelli MG (2013). Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. Colistimethate sodium. Pediatr Pulmonol, 48(1), 1-7.
  183. Zobell JT, Young DC, Waters D, Stockmann C, Ampofo K, Sherwin CM, Spigarelli MG (2013). Optimization of Anti-pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations: II. Cephalosporins and Penicillins. Pediatr Pulmonol, 48(2), 107-22.
  184. Zobell JT, Young DC, Waters CD, Stockmann C, Ampofo K, Sherwin CM, Spigarelli MG (2012). Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. Pediatr Pulmonol, 47(12), 1147-58. (Read full article)
  185. Zobell JT, Waters D, Young DC, Stockmann C, Ampofo K, Sherwin CM, Spigarelli MG (2012). Optimization of Anti-pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations: I. Aztreonam and Carbapenems. Pediatr Pulmonol, 47(12), 1147-58.
  186. Sherwin CM, Saldaa SN, Bies RR, Aman MG, Vinks AA (2012). Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents. Ther Drug Monit, 34(5), 535-44. (Read full article)
  187. Sherwin CM, Kiang TK, Spigarelli MG, Ensom MH (2012). Fundamentals of population pharmacokinetic modelling: validation methods. Clin Pharmacokinet, 51(9), 573-90. (Read full article)
  188. Kiang TK, Sherwin CM, Spigarelli MG, Ensom MH (2017). Fundamentals of Population Pharmacokinetic Modelling : Modelling and Software. Clin Pharmacokinet, 51(8), 515-525. (Read full article)
  189. Sherwin CM, Sagcal-Gironella AC, Fukuda T, Brunner HI, Vinks AA (2012). Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. Br J Clin Pharmacol, 73(5), 727-40. (Read full article)
  190. De Cock RF, Allegaert K, Schreuder MF, Sherwin CM, de Hoog M, van den Anker JN, Danhof M, Knibbe CA (2012). Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet, 51(2), 105-17. (Read full article)
  191. Zobell JT, Stockmann C, Young DC, Cash J, McDowell BJ, Korgenski K, Sherwin CM, Spigarelli M, Chatfield BA, Ampofo K (2011). Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients. Clin Ther, 33(11), 1844-50. (Read full article)
  192. Sagcal-Gironella AC, Sherwin CM, Tirona RG, Rieder MJ, Brunner HI, Vinks AA (2011). Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study. Clin Ther, 33(10), 1524-36. (Read full article)
  193. Sherwin CM, Ding L, Kaplan J, Spigarelli MG, Vinks AA (2011). Optimal study design for pioglitazone in septic pediatric patients. J Pharmacokinet Pharmacodyn, 38(4), 433-47. (Read full article)
  194. Merhar SL, Schibler KR, Sherwin CM, Meinzen-Derr J, Shi J, Balmakund T, Vinks AA (2011). Pharmacokinetics of levetiracetam in neonates with seizures. J Pediatr, 159(1), 152-154.e3. (Read full article)
  195. Sherwin CM, Ding L, Kaplan J, Spigarelli MG, Vinks AA (2011). Optimal study design for pioglitazone in septic pediatric patients. J Pharmacokinet Pharmacodyn, 38, 433-447.
  196. Sagcal-Gironella AC, Fukuda T, Wiers K, Cox S, Nelson S, Dina B, Sherwin CM, Klein-Gitelman MS, Vinks AA, Brunner HI (2011). Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum, 40, 307-313.
  197. Sagcal-Gironella AC, Fukuda T, Wiers K, Cox S, Nelson S, Dina B, Sherwin CM, Klein-Gitelman MS, Vinks AA, Brunner HI (2010). Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum, 40(4), 307-13. (Read full article)
  198. Merhar S, Schibler K, Sherwin C, Meinzen-Derr J, Shi J, Balmakund T, Vinks A (2011). Pharmacokinetics of levetiracetam in neonates with seizures. J Pediatr, 159(1). (Read full article)
  199. Sherwin CM, Fukuda T, Brunner HI, Goebel J, Vinks AA (2011). The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet, 50(1), 1-24. (Read full article)
  200. Sherwin CM, Svahn S, Van der Linden A, Broadbent RS, Medlicott NJ, Reith DM (2009). Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis. Eur J Clin Pharmacol, 65(7), 705-13. (Read full article)
  201. Sherwin CM, Kostan E, Broadbent RS, Medlicott NJ, Reith DM (2009). Evaluation of the effect of intravenous volume expanders upon the volume of distribution of gentamicin in septic neonates. Biopharm Drug Dispos, 30(5), 276-80. (Read full article)
  202. Sherwin CM, McCaffrey F, Broadbent RS, Reith DM, Medlicott NJ (2009). Discrepancies between predicted and observed rates of intravenous gentamicin delivery for neonates. J Pharm Pharmacol, 61(4), 465-71. (Read full article)
  203. Sherwin CM, Svahn S, van der Linden AJ, Medlicott NJ, Broadbent R, Reith DM (2009). Individualised Dosing of Amikacin in Neonates: a Pharmacokinetic/ Pharmacodynamic Analysis. Eur J Clin Pharmacol, 65(7), 705-13.
  204. Sherwin CM, Broadbent RS, Medlicott NJ, Reith DM (2008). Individualising netilmicin dosing in neonates. Eur J Clin Pharmacol, 64(12), 1201-8. (Read full article)
  205. Sherwin C, Broadbent R, Young S, Worth J, McCaffrey F, Medlicott NJ, Reith D (2008). Utility of interleukin-12 and interleukin-10 in comparison with other cytokines and acute-phase reactants in the diagnosis of neonatal sepsis. Am J Perinatol, 25(10), 629-36. (Read full article)
  206. Sherwin CM, Medlicott NJ, Broadbent RS and Reith DM (2008). Neonatal sepsis and aminoglycosides. April(4), 16-21.
  207. Mishra S, Storer MK, Sherwin CM, Lewis JG (2005). A simple binding assay for the direct determination of biotin in urine. Clin Chim Acta, 360(1-2), 60-6. (Read full article)

Review

  1. Shabanian Boroujeni Z, Heidari-Soureshjani S, Sherwin CMT (2024). Effects of Curcuma longa (turmeric) and curcumin on the premenstrual syndrome and dysmenorrhea: A systematic review. [Review]. J Endometr Pelvic Pain Disord, 16(1), 33-44. (Read full article)
  2. Forootan M, Amiri MM, Darvishi M, Sherwin CMT, Ghanadi K (2024). The Therapeutic Effects of Bromelain against Colorectal Cancer: A Systematic Review. [Review]. Curr Cancer Ther Rev, 20(4), 402-409. (Read full article)
  3. Khosravi MR, Raeisi E, Heidari-Soureshjani S, Sherwin CMT (2024). The survey of antitumor effects of bromelain on neoplastic breast cells: A systematic review. [Review]. Journal of HerbMed Pharmacology, 13(1), 10-18. (Read full article)
  4. Farsani HA, Heidari-Soureshjani S, Sherwin CMT, Tafrishi-Nejad A, Azadegan-Dehkordi Z (2024). The Analgesic Effect of Ginger on Postoperative Pain: A Systematic Review of Clinical Trials. [Review]. Nat Prod J, 14(2). (Read full article)
  5. Juberg DR, Fox DA, Forcelli PA, Kacew S, Lipscomb JC, Saghir SA, Sherwin CM, Koenig CM, Hays SM, Kirman CR (2023). A perspective on In vitro developmental neurotoxicity test assay results: An expert panel review. [Review]. Regul Toxicol Pharmacol, 143, 105444. (Read full article)
  6. Hudson RE, Metz TD, Ward RM, McKnite AM, Enioutina EY, Sherwin CM, Watt KM, Job KM (2023). Drug exposure during pregnancy: Current understanding and approaches to measure maternal-fetal drug exposure. [Review]. Front Pharmacol, 14, 1111601. (Read full article)
  7. Sayre CL, Yellepeddi VK, Job KM, Krepkova LV, Sherwin CMT, Enioutina EY (2023). Current use of complementary and conventional medicine for treatment of pediatric patients with gastrointestinal disorders. [Review]. Front Pharmacol, 14. (Read full article)
  8. Sayre CL, Yellepeddi VK, Job KM, Krepkova LV, Sherwin CMT, Enioutina EY (2023). Current use of complementary and conventional medicine for treatment of pediatric patients with gastrointestinal disorders. [Review]. Front Pharmacol, 14, 1051442. (Read full article)
  9. Kasiri K, Sherwin CMT, Rostamian S, Heidari-Soureshjani S (2023). Assessment of the Relationship Between Gastric-Acid Suppressants and the Risk of Esophageal Adenocarcinoma: A Systematic Review and Meta-Analysis. [Review]. Curr Ther Res Clin Exp, 98, 100692. (Read full article)
  10. Hudson RE, Metz TD, Ward RM, McKnite AM, Enioutina EY, Sherwin CM, Watt KM, Job KM (2023). Drug exposure during pregnancy: Current understanding and approaches to measure maternal-fetal drug exposure. [Review]. Front Pharmacol, 14. (Read full article)
  11. Emami E, Talebi-Boroujeni P, Sherwin CMT, Heidari-Soureshjani S, Mohammadi S (2023). Effect of Curcumin on Oxidative Stress, Inflammatory Response and Kidney Biochemical Parameters Among Kidney Disease Patients: A Systematic Review. [Review]. Nat Prod J, 13(5), 86-97. (Read full article)
  12. Ghahfarrokhi SH, Heidari-Soureshjani S, Talebi-Boroujeni P, Sherwin CMT (2023). Effect and Mechanism of Curcumin on Bone Loss and Osteoporosis: A Systematic Review. [Review]. Current Traditional Medicine, 9(6), 145-154. (Read full article)
  13. Kasiri K, Sherwin CMT, Rostamian S, Heidari-Soureshjani S (2023). Assessment of the Relationship Between Gastric-Acid Suppressants and the Risk of Esophageal Adenocarcinoma: A Systematic Review and Meta-Analysis. [Review]. Curr Ther Res Clin Exp, 98. (Read full article)
  14. Avachat C, Barry JM, Lyu X, Sherwin CM, Birnbaum AK (2022). Management of Anti-Seizure Medications during Pregnancy: Advancements in The Past Decade. [Review]. Pharmaceutics, 14(12). (Read full article)
  15. Avachat C, Barry JM, Lyu X, Sherwin CM, Birnbaum AK (2022). Management of Anti-Seizure Medications during Pregnancy: Advancements in The Past Decade. [Review]. Pharmaceutics, 14(12). (Read full article)
  16. Farahbod F, Talebi-Boroujeni P, Sherwin CMT, Heidari-Soureshjani S (2022). Effectiveness of phosphodiesterase type 5 inhibitors on the treatment of thin endometrium and pregnancy outcomes: An systematic review. [Review]. J Endometr Pelvic Pain Disord, 14(3), 132-142. (Read full article)
  17. Habibi Ghahfarrokhi S, Mohammadian-Hafshejani A, Sherwin CMT, Heidari-Soureshjani S (2022). Relationship between serum vitamin D and hip fracture in the elderly: a systematic review and meta-analysis. [Review]. J Bone Miner Metab, 40(4), 541-553. (Read full article)
  18. Hudson RE, Job KM, Sayre CL, Krepkova LV, Sherwin CM, Enioutina EY (2022). Examination of Complementary Medicine for Treating Urinary Tract Infections Among Pregnant Women and Children. [Review]. Front Pharmacol, 13. (Read full article)
  19. Hudson RE, Job KM, Sayre CL, Krepkova LV, Sherwin CM, Enioutina EY (2022). Examination of Complementary Medicine for Treating Urinary Tract Infections Among Pregnant Women and Children. [Review]. Front Pharmacol, 13, 883216. (Read full article)
  20. Sherwin CMT, Heidari-Soureshjani S (2022). Effects and Mechanisms of Medicinal Plants on Healing Scars: A Systematic Review. [Review]. Current Traditional Medicine, 8(1). (Read full article)
  21. Kingma JS, Burgers DMT, Monpellier VM, Wiezer MJ, Bluss van Oud-Alblas HJ, Vaughns JD, Sherwin CMT, Knibbe CAJ (2021). Oral drug dosing following bariatric surgery: General concepts and specific dosing advice. [Review]. Br J Clin Pharmacol, 87(12), 4560-4576. (Read full article)
  22. Krepkova LV, Babenko AN, Saybel OL, Lupanova IA, Kuzina OS, Job KM, Sherwin CM, Enioutina EY (2021). Valuable Hepatoprotective Plants - How Can We Optimize Waste Free Uses of Such Highly Versatile Resources? [Review]. Front Pharmacol, 12. (Read full article)
  23. Krepkova LV, Babenko AN, Saybel OL, Lupanova IA, Kuzina OS, Job KM, Sherwin CM, Enioutina EY (2021). Valuable Hepatoprotective Plants - How Can We Optimize Waste Free Uses of Such Highly Versatile Resources? [Review]. Front Pharmacol, 12, 738504. (Read full article)
  24. Job KM, Roberts JK, Enioutina EY, Illamola SM, Kumar SS, Rashid J, Ward RM, Fukuda T, Sherbotie J, Sherwin CM (2021). Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients. [Review]. Expert Opin Drug Metab Toxicol, 17(7), 747-765. (Read full article)
  25. Mohammadian-Hafshejani A, Sherwin CMT, Heidari-Soureshjani S (2020). Do statins play any role in reducing the incidence and mortality of ovarian cancer? A systematic review and meta-analysis. [Review]. J Prev Med Hyg, 61(3), E331-E339. (Read full article)
  26. Enioutina EY, Job KM, Krepkova LV, Reed MD, Sherwin CM (2020). How can we improve the safe use of herbal medicine and other natural products? A clinical pharmacologist mission. [Review]. Expert Rev Clin Pharmacol, 13(9), 935-944. (Read full article)
  27. Thyagarajan A, Alshehri M, Miller K, Sherwin C, Travers J, Sahu R (2019). Myeloid-derived suppressor cells and pancreatic cancer: Implications in novel therapeutic approaches. [Review]. Cancers (Basel), 11(11). (Read full article)
  28. Yellepeddi V, Rower J, Liu X, Kumar S, Rashid J, Sherwin CM (2018). State-of-the-Art Review on Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development. [Review]. Clin Pharmacokinet.
  29. Enioutina EY, Brown J, Fateeva TV, Teng L, Job KM, Bortnikova VV, Krepkova LV, Gubarev MI, Sherwin CM (2017). Phytotherapy as an alternative to conventional antimicrobials: Combating microbial resistance. [Review]. Expert Rev Clin Pharmacol, 10(11), 1203-1214.
  30. Linakis MW, Job KM, Liu X, Collingwood SC, Pangburn HA, Ott DK, Sherwin CM (2017). Riding (High) into the Danger Zone: A Review of Potential Differences in Chemical Exposures in Fighter Pilots Resulting from High Altitude and G-forces. [Review]. Expert Opin Drug Metab Toxicol, 13(9), 925-934.
  31. Tak CR, Job KM, Schoen-Gentry K, Campbell SC, Carroll P, Costantine M, Brixner D, Birnbaum AK, Sherwin CM (2017). The impact of exposure to antidepressant medications during pregnancy on neonatal outcomes: a review of retrospective database cohort studies. [Review]. Eur J Clin Pharmacol, (Jun 9).
  32. Grimsrud KN, Sherwin CMT, Constance JE, Tak C, Zuppa AF, Spigarelli MG, Mihalopoulos NL (2015). Special population considerations and regulatory affairs for clinical research. [Review]. Clin Res Regul Aff, 32(2), 47-56. (Read full article)
  33. Lala AC, Broadbent RS, Medlicott NJ, Sherwin CMT, Reith DM (2015). Illustrative neonatal cases regarding drug delivery issues. [Review]. J Paediatr Child Health, 51(5), 478-481. (Read full article)
  34. Kaur I, Constance JE, Kosak KM, Spigarelli MG, Sherwin CM (2015). An extensive pharmacokinetic, metabolic and toxicological review of elderly patients under intensive chemotherapy for acute myeloid leukemia. [Review]. Expert Opin Drug Metab Toxicol, 11(1), 53-65. (Read full article)
  35. Campbell SC, Spigarelli MG, Courter J, Sherwin CM (2013). Metabolic and toxicological considerations for sepsis drug treatments. [Review]. Expert Opin Drug Metab Toxicol, 9(1), 79-89. (Read full article)
  36. Kiang TK, Sherwin CM, Spigarelli MG, Ensom MH (2012). Fundamentals of population pharmacokinetic modelling: modelling and software. [Review]. Clin Pharmacokinet, 51(8), 515-25. (Read full article)

Edited Book

  1. Ene E, Bunbridge R, Bies R, Sherwin CM (Eds.) (In Press). Pharmacometrics: The Science of Quantitative Pharmacology. (2nd Edition). New York: Wiley-Interscience.

Book Chapter

  1. Stockmann C, Roberts JK, Savic RM, Sherwin CM (In Press). Design and analysis of Pediatric Clinical Trials. In Ene E, Bunbridge R, Bies R, Sherwin CM (Eds.), Pharmacometrics: The Science of Quantitative Pharmacology (Second edition). New York: Wiley-Interscience.
  2. Kumar SS, Duong JK, Liu X, Sherwin CM (In Press). Clinical Trial Simulation. In Ene E, Bunbridge R, Bies R, Sherwin CM (Eds.), Pharmacometrics: The Science of Quantitative Pharmacology (Second Edition). New York: Wiley-Interscience.
  3. Yellepeddi VK, Roberts JK, Escobar L, Sayre C, Sherwin CM (2018). The Relationship Between Pharmacogenomics and Pharmacokinetics and Its Impact on Drug Choice and Dosing Regimens in Pediatrics. In Yellepeddi VK|Roberts JK|Escobar L|Sayre C|Sherwin CM (Ed.), ADME Processes in Pharmaceutical Sciences: Dosage, Design, and Pharmacotherapy Success (pp. 203-222). (Read full article)
  4. De Cock PAJG, Allegaert K, Linakis MW, Sherwin CMT (2017). Antibiotic dosing in pediatric critically Ill patients. In De Cock PAJG|Allegaert K|Linakis MW|Sherwin CMT (Ed.), Antibiotic Pharmacokinetic/Pharmacodynamic Considerations in the Critically Ill (pp. 239-263). (Read full article)
  5. Krekels EHJ, Rower JE, Constance JE, Knibbe CAJ, Sherwin CMT (2017). Hepatic Drug Metabolism in Pediatric Patients. In Krekels EHJ|Rower JE|Constance JE|Knibbe CAJ|Sherwin CMT (Ed.), Drug Metabolism in Diseases (pp. 181-206). (Read full article)
  6. de Cock, PAJG, Allegaert, K, Linakis, MW, Sherwin CM (2017). Antibiotic dosing in paediatric critically ill patients. In Udy A, Roberts J, Lipman J (Eds.), Antibiotic pharmacokinetic/pharmacodynamic considerations in the critically ill (First Edition, pp. 239-263). New York: Springer-Adis Publishing.
  7. Campbell SC, Salisbury LM, Roberts JK, Kamyar M, Fredrickson J, Costantine MM, Sherwin CM (2016). Therapeutic Drug Monitoring in Pregnancy. In W Clarke, A Dasgupta (Eds.), Clinical Challenges in Therapeutic Drug Monitoring: Special Populations, Physiological Conditions and Pharmacogenomics (First Edition, pp. 185-211). Elsevier.
  8. Krekels EHJ, Rower JE, Constance JE, Knibbe CAJ, Sherwin CM (2017). Hepatic Drug Metabolism in Pediatric Patients. In Xie, W (Eds.), Drug Metabolism in Diseases (First, pp. 181–206). Elsevier Inc.
  9. Campbell S, Salisbury L, Roberts J, Kamyar M, Fredrickson J, Costantine M, Sherwin C (2016). Therapeutic Drug Monitoring in Pregnancy. In Campbell S|Salisbury L|Roberts J|Kamyar M|Fredrickson J|Costantine M|Sherwin C (Ed.), Clinical Challenges in Therapeutic Drug Monitoring: Special Populations, Physiological Conditions, and Pharmacogenomics (pp. 185-211). (Read full article)

Conference Proceedings

  1. Ivanova X, Liu X, Tran V, Sullivan K, Wead S, Neely A, Kagan R, Healy D, Sherwin CM (2018). Influence of Demographic and Clinical Variables on Vancomycin Trough Values in Pediatric Burn Patients. Annual Burn Association Meeting, Chicago IL, Journal of Burn Care & Research, 39(suppl 1), S73-S73.
  2. Grimsrud KN, Ivanova X, Sherwin CM, Palmieri T, Tran NK (2018). Identification of Cytochrome P450 Polymorphisms in Burn Patients and Impact on Fentanyl Pharmacokinetics. Annual Burn Association Meeting, Chicago IL, Journal of Burn Care & Research, 39(suppl 1), S34-S34.
  3. Balch AH, Kumar SS, Rower J, Illamola SM, Liu X, Korgenski K, Yoo J, Kim H, Wang J, Zhang X, Sherwin CM (2018). Statistical Properties of the pAUC metric in Pediatric Kidney Patients receiving Tacrolimus. American Society for Clinical Pharmacology and Therapeutics, ASCPT 2018, Orlando FL.
  4. Liu X, Wang Y, Sherwin CM (2018). Evaluating the performance of classical pk models, 2nd-gen MPBPK models and MPBPK models with TMDD in predicting therapeutic monoclonal antibody PK in human. American Society for Clinical Pharmacology and Therapeutics (ASCPT), Orlando, FL, Clinical Pharmacology & Therapeutics, 103, S78-S78.
  5. Biltaji E, Korgenski EK, Sherwin CM, Constance JE (2018). Predictors of liver toxicity associated with voriconazole exposure among pediatric and young adult patients. American Society for Clinical Pharmacology and Therapeutics, (ASCPT) Orlando FL, Clinical Pharmacology & Therapeutics, 103, S25-S25.
  6. Plumage E, Illamola S, Balch A, Sherwin CM (2018). Therapeutic Drug Monitoring in Pediatric Heart Transplant Patients Receiving Mycophenolate Mofetil. American Society for Clinical Pharmacology and Therapeutics, ASCPT 2018, Orlando FL, Clinical Pharmacology &Therapeutics, 103, S47-S47.
  7. Huynh HQ, Illamola SM, Liu X, Bhakta Z, Sherwin CM, Liou TG, Carveth H, Young DC (2017). Population pharmacokinetics of intravenous amikacin in adult cystic fibrosis patients. North American Cystic Fibrosis Conference (NACF) 2017, Indianapolis, IN, Pediatric Pulmonology, 52, S366-S366.
  8. May L, Liu X, Sherwin CM, Yang L, Zehnder J, Lee J, Lo C, Chen S, Rosenthal DN, McElhinney DB, Almond CS (2017). Use of TEG/Platelet Mapping to Dose-Adjust Platelet Inhibitors in Children Supported with the Berlin EXCOR: In Search of a Correlation. The Journal of Heart and Lung Transplantation, 36(4), S278-S279.
  9. Balch AH, Constance J, Kumar SS, Korgenski EK, Sherbotie JR, Yu T, Sherwin CM (2017). Do physicians change tacrolimus dosing after 90 days? An EMR-based study of therapeutic drug monitoring in transplant patients. American Society for Clinical Pharmacologyand Therapeutics (ASCPT), Washington DC: Clinical Pharmacology & Therapeutics, 101(S1), S56.
  10. Linakis MW, Liu X, Cook SF, Kumar SS, Wilkins DG, Gaedigk R, Gaedigk A, Sherwin CM, van den Anker JN (2017). UGT1A9 RS3832043 influences acetaminophen glucuronidation in neonates. American Society for Clinical Pharmacologyand Therapeutics (ASCPT), Washington, DC: Clinical Pharmacology & Therapeutics, 101(S1), S8.
  11. Liu X, Smits A, Wang Y, Wead S, Kagan RJ, Healy DP, de Cock P, Allegaert K, Sherwin CM (2017). Dosing Optimization of Amikacin in Pediatric Patients with Burn Injuries and Those with Oncology Conditions. American Society for Clinical Pharmacology and Therapeutics (ASCPT), Washington DC: Clinical Pharmacology & Therapeutics, 101(S1).
  12. Wang Y, Liu X, Olson J, Korgenski EK, Thorell EA, Sherwin CM (2017). Population pharmacokinetic modeling and dosing regimen optimization of intravenous gentamicin in pediatric population. American Society for Clinical Pharmacology and Therapeutics (ASCPT), Washingon, DC: Clinical Pharmacology & Therapeutics, 101(S1).
  13. Liu X, Jones BL, Roberts JK, Sherwin CM (2017). Population pharmacokinetic/pharmacodynamics modeling of histamine response measured by histamine iontophoresis laser Doppler. American Society for Clinical Pharmacology and Therapeutics (ASCPT), Washington, DC: Clinical Pharmacology & Therapeutics, 101(S1).
  14. Job KM, Sanders C, Hillyard B, Rower JE, Korgenski EK, Sherwin CM (2017). Trends of Calcineurin Inhibitor Use in Pediatric Immunosuppression. American Society for Clinical Pharmacology and Therapeutics (ASCPT), Washington, DC: Clinical Pharmacology & Therapeutics, 101(S1).
  15. Ivanova X, Liu X, Tran N, Wead S, Kagan RJ, Healy DP, Sherwin CM (2017). Pharmacokinetic Model for Vancomycin in Pediatric Burn Patients. American Society for Clinical Pharmacology and Therapeutics (ASCPT), Washington, DC: Clinical Pharmacology & Therapeutics, 101(S1).
  16. Kumar SS, Liu X, Sherwin CM, Jones BL (2017). Determining the Reliability of Histamine response phenotype classification: a population modelling approach. American Society for Clinical Pharmacology and Therapeutics (ASCPT), Washington, DC: Clinical Pharmacology & Therapeutics, 101(S1).
  17. Yu T, Rower JE, Liu X, Balch A, Halford Z, Korgenski EK, Sherwin CM (2016). Development of a physiologically based Pharmacokinetic model of tacrolimus in adult organ transplant patients. American Society for Clinical Pharmacology and Therapeutics, ASCPT, San Diego, CA: Clinical Pharmacology & Therapeutics, 99, S71-S71.
  18. Constance JE, Stockmann C, Linakis M, Balch A, Korgenski EK, Spraker-Perlman H, Lemons R, Sherwin CM (2016). Use of supportive care therapies among pediatric cancer patients with hematologic malignancies undergoing chemotherapy. American Society for Clinical Pharmacology and Therapeutics, ASCPT, San Diego, CA: Clinical Pharmacology & Therapeutics, 99, S90-S90.
  19. Rower JE, Liu X, Yu T, Mundorff M, Sherwin CM, Johnson M (2016). Population pharmacokinetic modeling of magnesium sulfate for treatment of severe acute asthma in children in an emergency room setting. American Society for Clinical Pharmacology and Therapeutics, ASCPT, San Diego, CA: Clinical Pharmacology & Therapeutics, 99, S92-S93.
  20. Abdelaziz S, Yu T, Stockmann C, Sherwin CM, Constance JE, Balch A (2016). Changes in pediatric prescribing patterns during Therapeutic drug monitoring of tacrolimus. American Society for Clinical Pharmacology and Therapeutics, ASCPT, San Diego, CA: Clinical Pharmacology & Therapeutics.
  21. Linakis MW, Cook SF, Rower JE, Rollins DE, Sherwin CM, Wilkins DG (2016). Pharmacokinetics and renal clearance of beta-hydroxy-betamethylbutyrate in healthy adults. American Society for Clinical Pharmacology and Therapeutics, ASCPT, San Diego, CA: Clinical Pharmacology & Therapeutics.
  22. Enioutina EY, Balch A, Wilkes J, Olsen J, Thorell E, Pavia AT, Sherwin CM (2016). IVIG use among children in freestanding children’s hospitals in the United States. American Society for Clinical Pharmacology and Therapeutics, ASCPT, San Diego: Clinical Pharmacology & Therapeutics.
  23. Liu X, Balch A, Dixon CL, Costantine MM, Sherwin CM (2016). Logistic modeling of cord blood magnesium level and cerebral palsy incidence in children with maternal magnesium sulfate dosing. American Society for Clinical Pharmacology and Therapeutics, ASCPT, San Diego: Clinical Pharmacology & Therapeutics.
  24. Liu X, Lieh-lai MW, Kauffman RE, Ward RM, Sherwin CM (2016). Population pharmacokinetic modeling of morphine and Metabolites in 3-18 year-old children following surgery. American Society for Clinical Pharmacology and Therapeutics, ASCPT, San Diego, CA: Clinical Pharmacology & Therapeutics.
  25. Constance JE, Stockmann C, Linakis M, Balch A, Korgenski EK, Spraker-Perlman H, Lemons R, Sherwin CM (2016). Use of supportive care therapies among pediatric cancer patients with hematologic malignancies undergoing chemotherapy. ASCPT Pre-conference Challenges in Global Drug Development and Regulation Quantitative Translational Approaches in Oncology, San Diego, CA: Clinical Pharmacology and Therapeutics.
  26. Liu X, Smits A, Yu T, Wead S, Neely AN, Kagan RJ, Healy DP, Allegaert K, Sherwin CM (2016). Amikacin pharmacokinetics in Pediatric patients with burn injuries compared to those with oncology conditions. World Conference of Pharmacometrics (WCoP), Brisbane, Australia.
  27. Wang Y, Liu X, Korgenski EK, Sherwin CM (2016). Population pharmacokinetic modeling of gentamicin in pediatric patients and assessment of age influence. American Conference on Pharmacometrics (ACoP).
  28. Liu X, Tak C, Sherwin CM, Shakib JH (2016). Exploring maternal-infant linked influenza antibody kinetics using a unified population model. American Conference on Pharmacometrics (ACoP), Bellevue, WA.
  29. Wang Y, Liu X, Constance JE, Korgenski EK, Sherwin CM (2016). Population pharmacokinetic modeling of gentamicin in children diagnosed with cancer. American Association of Pharmaceutical Scientists (AAPS).
  30. Liu X, Yu T, Dobson NR, McEntire BL, Ward RM, Spigarelli MG, Hunt CE, Sherwin CM (2015). Pharmacokinetic modelling of plasma and salivary caffeine circulation in infants receiving extended caffeine therapy for intermittent hypoxia treatment. American Conference on Pharmacometrics (ACoP), Crystal City, VA, Crystal City, VA: Journal of Pharmacokinetics and Pharmacodynamics, 42, S95-S96.
  31. Yu T, Sinha M, Stockmann C, Hillard MA, Spigarelli MG, Russell SJ, Sherwin CM (2015). Population pharmacokinetics of glucagon administered by subcutaneous or intradermal route in patients with type 1 diabetes. European Association for Clinical Pharmacology and Therapeutics (EACPT), Spain, Madrid: Clinical Therapeutics, 37(8), e15.
  32. Sinha M, Yu T, Sherwin CM, Hillard MA, Spigarelli MG, Russell SJ (2015). Comparison of the Intradermal vs. Subcutaneous Delivery of Insulin and Glucagon in T1DM. American Diabetes Association (ADA) Annual Meeting 2015, Boston, Massachusetts, Diabetes, 64, A276-A276.
  33. Yu T, Sinha M, Hillard MA, Sherwin CM, Russell SJ, Spigarelli MG (2015). Population Pharmacokinetics of Intradermal versus Subcutaneous Insulin Delivery in Patients with Type 1 Diabetes. American Society for Clinical Pharmacology and Therapeutics, ASCPT 2015, New Orleans, LA: Clinical Pharmacology & Therapeutics, 97, S48-S49.
  34. Stockmann C, Hersh AL, Ampofo K, Byington CL, Sherwin CM, Spigarelli MG, Pavia AT (2014). National Estimates of Pediatric Infectious Disease Hospitalizations from 1997-2009: An Analysis of the Kids’ Inpatient Database. Infectious Diseases Society of America (IDSA) Annual Meeting, Philadelphia, PA, Open Forum Infectious Diseases, 1, S4-S4.
  35. Kamyar M, Balch A, Campbell S, Robertson J, Sherwin CM, Clark EAS, Spigarelli MG, Rose N (2014). The Evaluation of Teratogen Information Service Data as it Relates to Prenatal Care. Society for Gynecologic Investigation, 61st Annual Meeting, Florence, Italy: Reproductive Sciences, 21(3), 254A-254A.
  36. Yu T, Schoen K, Tak C, Clark EA, Varner MV, Spigarelli MG, Sherwin CM (2014). Population Pharmacokinetics of Caffeine and Its Metabolites in Pregnant Women. American Society for Clinical Pharmacology and Therapeutics, ASCPT, Atlanta, GA: Clinical Pharmacology & Therapeutics, 95, S94-S94.
  37. Campbell SC, Stockmann C, Sherwin CM, Spigarelli MG (2014). Examination of Gentamicin and Magnesium Sulfate Drug-Drug Interactions in Neonates. American Society for Clinical Pharmacology and Therapeutics, ASCPT, Atlanta, GA: Clinical Pharmacology & Therapeutics.
  38. Firth SD, Yakub SY, Sherwin CM, Korgenski K, Constance JE, Stockmann C, Balch A, Spigarelli MG (2014). Therapeutic Monitoring of Vancomycin in Children: Is There a Cost to Non-adherence of Guidelines? American Society for Clinical Pharmacology and Therapeutics, ASCPT, Atlanta, GA: Clinical Pharmacology & Therapeutics, 95, S56-S56.
  39. Constance JE, Balch A, Stockmann C, Sherwin CM, Spigarelli MG (2014). Characteristics of Pediatric Cancer Patients Receiving Vancomycin. American Society for Clinical Pharmacology and Therapeutics, ASCPT, Atlanta, GA: Clinical Pharmacology & Therapeutics, 95, S55-S55.
  40. Roberts JK, Sherwin CM, Beachy J, Ward RM, Baserga M, Spigarelli MG (2014). Pharmacokinetics of Darbepoetin Alfa in the Treatment of Hypoxic-Ischemic Encephalopathy. American Society for Clinical Pharmacology and Therapeutics, ASCPT, Atlanta, GA: Clinical Pharmacology & Therapeutics, 95, S99-S99.
  41. Balch AH, Thorell E, Constance J, Stockmann C, Korgenski K, Spigarelli MG, Sherwin CM (2014). Factors Influencing Vancomycin Dose Reduction in Neonatal and Pediatric Patients. American Society for Clinical Pharmacology and Therapeutics, ASCPT, Atlanta, GA: Clinical Pharmacology & Therapeutics, 95, S54-S55.
  42. Bhongsatiern J, Sherwin CM, Stockmann C, Yu T, Reith DM, Desai PB, Spigarelli MG (2014). An improved vancomycin dosing strategy in neonates using population pharmacokinetics and simulations to achieve pharmacodynamic target attainment. American Society for Clinical Pharmacology and Therapeutics (ASCPT), Atlanta, GA: Clinical Pharmacology & Therapeutics.
  43. Roberts J, Beachy J, Yoder B, Ward R, Sherwin CM, Spigarelli MG, DiGeronimo R, Ohls R, Walsh W, Mayock D, Juul S, Christensen R, Baserga M (2014). DANCE (Darbe administration in newborns undergoing cooling for encephalopathy): safety and pharmacokinetic trial. Western Society for Pediatric Research (WSPR), Carmel, CA: Journal of Investigation Medicine, 62(1), 210-210.
  44. Green A, Campbell SC, Thomas K, Sherwin CM, Spigarelli MG (2013). Medication Exposures during Pregnancy and Breastfeeding. 13th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Salt Lake City, UT, Salt Lake City, UT: Therapeutic Drug Monitoring, 35(5), 704-704.
  45. Bhongsatiern J, Stockmann C, Yu T, Reith DM, Sherwin CM, Desai P, Spigarelli MG (2013). An External Evaluation of Vancomycin Pharmacokinetics Among Septic Neonates. 13th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Salt Lake City, UT: Therapeutic Drug Monitoring, 35(5), 664-664.
  46. Bridges ZM, Campbell SC, Thomas K, Sherwin CM, Spigarelli MG (2013). Poison Control Center Calls Regarding Exposures to Pregnant and Breastfeeding Women. 13th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Salt Lake City, UT: Therapeutic Drug Monitoring, 35(5), 718-719.
  47. Yu T, Sherwin CM, Balch A, Ward R, Spigarelli MG (2013). Population pharmacokinetics of caffeine in neonates and infants to improve therapeutic range attainment. 13th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Salt Lake City, UT, Salt Lake City, UT: Therapeutic Drug Monitoring, 35(5), 715-715.
  48. Constance JE, Balch A, Campbell SC, Stockmann C, Sherwin CM, Spigarelli MG (2013). Frequency of achieving the therapeutic range with vancomycin in infants, children and adolescents. 13th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Salt Lake City, UT: Therapeutic Drug Monitoring, 35(5), 674-647.
  49. Linakis MW, Constance J, Stockmann C, Campbell S, Sherwin CM, Spigarelli MG (2013). Frequency of Vancomycin Target Trough Attainment for Cutaneous and Invasive Staphylococcal Infections. 13th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Salt Lake City, UT, Salt Lake City, UT: Therapeutic Drug Monitoring, 35(5), 697-697.
  50. Campbell SC, McMillin G, Sherwin CM, Spigarelli MG (2013). Thiopurine Methyltransferase Pharmacogenomic Testing: Known But Infrequently Done. 13th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Salt Lake City, UT: Therapeutic Drug Monitoring, 35(5), 714-715.
  51. Weston AS, Constance JE, Campbell SC, Stockmann C, Mihalopoulos NL, Sherwin CM, Spigarelli MG (2013). Dosing Vancomycin in Pediatric Patients with Obesity. 13th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Salt Lake City, UT: Therapeutic Drug Monitoring, 35(5), 688-689.
  52. Firth SD, Yakub SY, Sherwin CM, Constance JE, Balch A, Spigarelli MG (2013). Therapeutic monitoring of Vancomycin in neonates: Is there a cost to non-adherence of guidelines? 13th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Salt Lake City, UT, Salt Lake City, UT: Therapeutic Drug Monitoring, 35(5), 681-681.
  53. Stockmann C, Sherwin CM, Constance J, Campbell SC, Linakis M, Yu T, Balch A, Spigarelli MG (2013). Paediatric Under Representation in Therapeutic Drug Monitoring Studies. 13th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Salt Lake City, UT, Salt Lake City, UT: Therapeutic Drug Monitoring, 35(5), 674-675.
  54. Stockmann C, Sherwin CM, Spigarelli MG (2013). Published Therapeutic Drug Monitoring Studies: Who Is Supporting Research? 13th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Salt Lake City, UT: Therapeutic Drug Monitoring, 35(5), 706-706.
  55. Yu T, Stockmann C, Balch A, Sherwin CM, Spigarelli MG (2013). Characteristics and Trends of Vancomycin Clinical Trials Registered in the United States from 1997-2012. 13th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Salt Lake City, UT: Therapeutic Drug Monitoring, 35(5), 716-716.
  56. Firth SD, Yakub SY, Sherwin CM, Constance JE, Balch A, Spigarelli MG (2013). Assessment of Therapeutic Guideline Adherence for Vancomycin Use in Neonates. 13th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Salt Lake City, UT: Therapeutic Drug Monitoring, 35(5), 700-700.
  57. Sherwin CM, Stockmann C, Zobell JT, McCrory B, Wisdom M, Young DC, Olson J, Ampofo K, Spigarelli MG (2013). A Pharmacokinetic Evaluation of Tobramycin Administered One, Two, and Three Times Daily to Children with Cystic Fibrosis. American Conference on Pharmacometrics (ACoP), Fort Lauderdale, FL: Journal of Pharmacokinetics and Pharmacodynamics, 40, S131-S131.
  58. Stockmann C, Sherwin CM, Zobell JT, Lubsch L, Young DC, Olson J, Noyes BE, Ampofo K, Spigarelli MG (2013). Population Pharmacokinetics of Vancomycin Used in the Treatment of Pediatric Cystic Fibrosis Pulmonary Exacerbations. American Conference on Pharmacometrics (ACoP), Fort Lauderdale, FL: Journal of Pharmacokinetics and Pharmacodynamics, 40, S132-S132.
  59. Yakub SY, Campbell SC, Sherwin CM, Constance J, Balch A, Spigarelli MG (2013). Trends of use of vancomycin in neonates. American Society for Clinical Pharmacology and Therapeutics, ASCPT, Indianapolis, Indiana: Clinical Pharmacology & Therapeutics, 93, S49-S50.
  60. Campbell SC, Sherwin CM, Balch AH, Clark EA, Spigarelli MG (2013). Examination of intrapartum use of magnesium sulfate and potential drug-drug interactions. American Society for Clinical Pharmacology and Therapeutics, ASCPT, Indianapolis, Indiana: Clinical Pharmacology & Therapeutics, 93, S20-S20.
  61. Fredrickson J, Balch A, Campbell SC, Sherwin CM, Clark EA, Spigarelli MG (2013). Intrapartum use of magnesium sulfate and the relationship between maternal and neonatal magnesium blood levels. American Society for Clinical Pharmacology and Therapeutics, ASCPT, Indianapolis, Indiana: Clinical Pharmacology & Therapeutics, 93, S48-S49.
  62. Constance JE, Campbell SC, Linakis MW, Sherwin CM, Spigarelli MG (2013). Dosing of vancomycin in neonates: on target for the therapeutic range? American Society for Clinical Pharmacology and Therapeutics, ASCPT, Indianapolis, Indiana: Clinical Pharmacology & Therapeutics.
  63. Bhongsatiern J, C Stockmann C, Yu T, Spigarelli MG, Sherwin CM (2013). Neonatal population pharmacokinetics and pharmacodynamics modeling of vancomycin to simulate target exposure attainment. American Society for Clinical Pharmacology and Therapeutics, ASCPT, Indianapolis, Indiana: Clinical Pharmacology & Therapeutics.
  64. Jones BL, Sherwin CM, Neville KA, Spigarelli MG, Kearns GL, Leeder JS (2012). Evidence of distinct histamine pharmacodynamic phenotypes in children. American Society for Clinical Pharmacology and Therapeutics (ASCPT), Baltimore, MA, Clinical Pharmacology & Therapeutics, Supplement 1. (March 2012), 91, S28.
  65. De Cock RFW, Allegaert K, Sherwin CM, de Hoog M, van den Anker JN, Danhof M, Knibbe CAJ (2012). Maturation of glomerular filtration rate in preterm and term neonates as reflected by clearance of amikacin, netilmicin and vancomycin. American Society for Clinical Pharmacology and Therapeutics, Baltimore, MA: Clinical Pharmacology & Therapeutics, 91(Suppl. 1), S28.
  66. De Cock RFW, Allegaert K, de Hoog M, Sherwin CM, Danhof M, Knibbe CAJ (2011). Predicting glomerular filtration rate using clearance of amikacin in neonates–Model Evaluation. British Pharmacological Society, British Journal of Clinical Pharmacology, 72(5), 846-847.
  67. Zobell JT, Stockmann C, Young DC, Cash J, Sherwin CM, Spigarelli M, Chatfield BA, Ampofo K (2011). Population pharmacokinetic (PK) and pharmacodynamic (PD) modeling of ticarcillin-clavulanate in pediatric CF patients. North American Cystic Fibrosis (NACF) Conference, Anaheim, CA: Pediatr Pulmon, Suppl 34, 277.
  68. Saldana SN, Sherwin CM, Bies RR, Kuijvenhovem M, Aman M, Vinks AA (2011). Population Pharmacokinetics of Risperidone Using Sparse and D-Optimal Sampling in Children and Adolescents. American Society for Clinical Pharmacology and Therapeutics, Dallas, TX: Clinical Pharmacology & Therapeutics, 89, S56-S57.
  69. Sagcal-Gironella AC, Sherwin CM, Tirona RG, Rieder MJ, Brunner HI, Vinks AA (2011). Open-label, single dose pharmacokinetic study of prednisolone at steady state in young patients with SLE on prednisone therapy. European Association for Clinical Pharmacology and Therapeutics (EACPT), Budapest, Hungary: Clinical Therapeutics, 33(10), 1524.
  70. Sherwin CM, Sagcal-Gironella AC, Fukuda T, Brunner HI, Vinks AA (2010). Development of a population pharmacokinetic model with enterohepatic recirculation for mycophenolic acid in patients with childhood systemic lupus erythmatosus (cSLE). American Society for Clinical Pharmacology and Therapeutics (ASCPT), Atlanta, GA, Atlanta, GA: Clinical Pharmacology & Therapeutics, 87, S61-S61.
  71. Sherwin CM, McCaffrey F, Broadbent RS, Reith DM and Medlicott NJ (2008). Investigation Into the Intravenous Delivery of Aminoglycoside Antibiotics to Extremely Premature Neonates. 11th Biannual European Society for Developmental Perinatal and Pediatric Pharmacology Congress; Rotterdam, The Netherlands.
  72. Medlicott NJ, Sherwin CM, Broadbent R, McCaffrey F, Reith DM (2008). Intravenous Infusions of Gentamicin in Neonate Patients - Effects of Infusion Variables on Drug Administration Rates. Royal Pharmaceutical Society Conference, Manchester, UK: Journal of Pharmacy and Pharmacology, 60(26 Suppl.), A11.

Commentary

  1. Enioutina EY, Job KM, Sherwin CMT (2020). Why we need to pay attention to toxicity associated with herbal medicines. Br J Clin Pharmacol, 86(9), 1793-1794. (Read full article)

Editorial

  1. Chen F, Tuzun F, Sherwin CMT (2023). Editorial: Genetics and ontogeny in precision therapeutics for children. Front Genet, 14, 1308169. (Read full article)
  2. Sherwin CM (2023). Editorial: Publishing in 2023 and Beyond. Curr Ther Res Clin Exp, 98, 100706. (Read full article)
  3. Job KM, Roberts JK, Sherwin CM (2023). Editorial: Methods and protocols in obstetric and pediatric pharmacology: 2022. Front Pharmacol, 14, 1205963. (Read full article)
  4. Sherwin CM, Lin YS (2023). Editorial: Women in obstetric and pediatric pharmacology: 2021. Front Pharmacol, 14, 1191285. (Read full article)
  5. Chen F, Tuzun F, Sherwin CMT (2023). Editorial: Genetics and ontogeny in precision therapeutics for children. Front Genet, 14. (Read full article)
  6. Sherwin CM, Lin YS (2023). Editorial: Women in obstetric and pediatric pharmacology: 2021. Front Pharmacol, 14. (Read full article)
  7. Job KM, Roberts JK, Sherwin CM (2023). Editorial: Methods and protocols in obstetric and pediatric pharmacology: 2022. Front Pharmacol, 14. (Read full article)
  8. Sherwin CM (2023). Editorial: Publishing in 2023 and Beyond. Curr Ther Res Clin Exp, 98. (Read full article)
  9. Illamola SM, Birnbaum AK, Sherwin CM (2019). Generic drug products in paediatrics: Where are the data? Br J Clin Pharmacol, 85(9), 1871-1873. (Read full article)
  10. Kumar SS, Biltaji E, Bies R, Sherwin CM (2018). The clinical utility of pharmacometric models. Br J Clin Pharmacol, 84(7), 1413-1414. (Read full article)
  11. Biltaji E, Kumar SS, Enioutina EY, Sherwin CMT (2017). Can ad hoc analyses of clinical trials help personalize treatment decisions? Br J Clin Pharmacol, 83(11), 2337-2338. (Read full article)
  12. Biltaji E, Kumar SS, Enioutina EY, Sherwin CM (2017). Can ad hoc analyses of clinical trials help personalize treatment decisions? Br J Clin Pharmacol, 83(11), 2337-2338.
  13. Ward RM, Sherwin CM (2016). Newborns still lack drug data to guide therapy. Br J Clin Pharmacol, 82(6), 1410-1411. (Read full article)
  14. Allegaert K, Sherwin C (2016). Neonates and medicines: a roadmap to further improve neonatal pharmaceutical care. Eur J Pediatr, 175(6), 743-6. (Read full article)
  15. Allegaert K, Sherwin CM (2016). Neonates and medicines: a roadmap to further improve neonatal pharmaceutical care. Eur J Pediatr.
  16. Stockmann C, Constance JE, Roberts JK, Sherwin CM, Spigarelli MG (2014). How Not to Be a Successful Clinical Pharmacologist. Journal of Pharmacology & Clinical Toxicology, 2(2), 1027.

Letter

  1. Roberts JK, Linakis MW, Liu X, Sherwin CMT, van den Anker JN (2018). Evident bias in a paracetamol metabolite population pharmacokinetic model applied to an external dataset. [Letter to the editor]. Br J Clin Pharmacol, 84(7), 1628-1630. (Read full article)
  2. Roberts JK, Linakis MW, Liu X, Sherwin CM, van den Anker JN (2018). Evident bias in a paracetamol metabolite population pharmacokinetic model applied to an external dataset [Letter to the editor]. Br J Clin Pharmacol.
  3. Stockmann C, Sherwin CMT, Knackstedt ED, Hersh AL, Pavia AT, Spigarelli MG (2016). Therapeutic drug monitoring of ganciclovir treatment for cytomegalovirus infections among immunocompromised children [Letter to the editor]. J Pediatric Infect Dis Soc, 5(2), 231-232. (Read full article)
  4. Stockmann C, Sherwin CM, Knackstedt ED, Hersh AL, Pavia AT, Spigarelli MG (2016). Therapeutic Drug Monitoring of Ganciclovir Treatment for Cytomegalovirus Infections Among Immunocompromised Children. [Letter to the editor]. J Pediatric Infect Dis Soc, 5(2), 231-232. (Read full article)
  5. Stockmann C, Reilly CA, Fassl B, Gaedigk R, Nkoy F, Stone B, Roberts JK, Uchida DA, Leeder JS, Sherwin CM, Spigarelli MG, Yost GS, Ward RM (2015). Effect of CYP3A5*3 on asthma control among children treated with inhaled beclomethasone. [Letter to the editor]. J Allergy Clin Immunol, 136(2), 505-7. (Read full article)
  6. Stockmann C, Ross JS, Sherwin CMT, Reilly CA, McDowell B, Fassl B, Nkoy F, Maloney CG, Spigarelli MG (2014). Rate of asthma trial outcomes reporting on ClinicalTrials.gov and in the published literature. [Letter to the editor]. J Allergy Clin Immunol, 134(6), 1443-1446. (Read full article)
  7. Stockmann C, Ross JS, Sherwin CM, Reilly CA, McDowell B, Fassl B, Nkoy F, Maloney CG, Spigarelli MG (2014). Rate of asthma trial outcomes reporting on ClinicalTrials.gov and in the published literature [Letter to the editor]. J Allergy Clin Immunol, 134(6), 1443-1446.
  8. Allegaert K, Sherwin CM (2010). Amikacin in neonates: dosing recommendations should be based on both pharmacokinetics and dynamics. [Letter to the editor]. Singapore Med J, 51(1), 88-9. (Read full article)
  9. Sherwin CM, Broadbent RS, Medlicott NJ, Reith DM (2009). Individualised dosing of amikacin in neonates. [Letter to the editor]. Eur J Clin Pharmacol, 65(12), 1267-8. (Read full article)
  10. Sherwin CM, Broadbent R, Medlicott NJ, Reith DM (2009). Individualized Dosing of Amikacin in Neonates. [Letter to the editor]. Eur J Clin Pharmacol, 65(12), 1267-1268.
  11. Sherwin CM, Svahn S, Broadbent RS, Van Der Linden A, Medlicott NJ, Reith DM (2008). Netilmicin withdrawal: impact on neonates. [Letter to the editor]. N Z Med J, 121(1284), 95-7. (Read full article)

Abstract

  1. Balch AH, Wilkes J, Olson J, Thorell EA, Pavia AT, Sherwin CM, Enioutina EY (2018). IVIG use in pediatric cancer patients [Abstract]. American College of Clinical Pharmacology (ACCP) Annual Meeting, 2018. (Epub ahead of print)
  2. Kumar SS, Liu X, Illamola SM, Rashid J, Job K, Balch A, Rower J, Sherbotie J, Sherwin CM (2018). Tacrolimus population pharmacokinetics in paediatric kidney transplant patients [Abstract]. PAGE 27. Population Approach Group in Europe. Abstr 8791 [www.page-meeting.org/?abstract=8791], Montreux, Switzerland.
  3. Becker S, Job K, Rower J, Forbes T, Sherwin CM, Nelson D, Johnson M (2018). Pharmacokinetics of intravenous magnesium sulfate in status asthmaticus: A prospective cross-sectional analysis in a tertiary pediatric emergency department [Abstract]. Pediatric Academic Societies (PAS) 2018, Toronto, Canada.
  4. Becker S, Forbes T, Job K, Rower J, Sherwin CM, Nelson D, Johnson M (2018). Repeated Blood Samples for Measurement of Magnesium in Children with Severe Acute Asthma [Abstract]. Pediatric Academic Societies (PAS) 2018, Toronto, Canada.
  5. Biltaji E, Biskupiak JE, Sherwin CM, McMillin GA, Brixner DI (2018). Optimizing the value of pharmacogenetic risk screening among patients with polypharmacy: A healthcare system experience [Abstract]. Academy of Managed Care Pharmacy (AMCP) 2018, Boston, MA.
  6. Tak CR, Kim J, Gunning K, Ruble J, Sherwin CM, Nickman NA, Biskupiak J (2018). Effect of a Prescription Order Requirement for Pharmacist-Administered Vaccination on Zoster Vaccination Rates [Abstract]. Academy of Managed Care Pharmacy (AMCP) 2018, Boston, MA.
  7. Liu X, Smits A, Wang Y, Renard M, Wead S, Kagan RJ, Healy DP, De Cock P, Allegaert K, Sherwin CM (2018). Disease condition affects amikacin pharmacokinetics and dosing in children [Abstract]. European Academy of Pediatric Societies (EAPS) 2018.
  8. Rashid R, Kumar SS, Sinha M, Hillard MA, Liu X, Russell SJ, Sherwin CM (2018). Population pharmacokinetics of subcutaneously- and intradermally-administered glucagon in type 1 diabetic patients [Abstract]. American Association of Pharmaceutical Scientists (AAPS), 2018.
  9. Karanam A, Sherwin CM, Birnbaum A (2018). A PBPK model for modeling drug exposures of lamotrigine in breastfed infants [Abstract]. American Conference on Pharmacometrics (ACoP), 2018.
  10. Rashid J, Vaughns JD, Williams EF, Liu X, van den Anker J, Sherwin CM (2018). Population Pharmacokinetic Analysis of Enoxaparin in Obese Adolescents undergoing Bariatric Surgery [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Diego, CA.
  11. Kumar SS, Liu X, Kahanovitz L, Sherwin CM, Russell SJ (2017). Characterizing the absorption differences of insulin analogs using population pharmacokinetic analysis [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Diego, CA.
  12. Liu X, Wang Y, Sherwin CM (2017). Developing physiologically based pharmacokinetic models that predict drug exposure of therapeutic monoclonal antibodies for rheumatoid arthritis treatment [Abstract]. ACR/ARHP Annual Meeting.
  13. Liu X, Tak C, Sherwin CM, Shakib JH (2017). A Semi-physiological Maternal-infant Model for Influenza Antibody Kinetics And The Impact Of Maternal Immunization Effects [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Diego, CA.
  14. Fateeva T, Krutivova N, Krepkova L, Job K, Bortnikova V, Sherwin CM, Enioutina E (2017). Combating microbial resistance with phytodrugs [Abstract]. Keystone Symposia Conference, Antimicrobials and Resistance: Opportunities and Challenges, Santa Fe, New Mexico.
  15. Plumage EF, Illamola SM, Sherwin CM (2017). Use of Mycophenolate Mofetil in Pediatric Patients Receiving Heart Transplants [Abstract]. Society for Advancement of Chicanos/Hispanics and Native Americans in Science (SACNAS).
  16. Biltaji E, Korgenski EK, Sherwin, CM Constance JE (2017). Voriconazole therapeutic target attainment among pediatric patients [Abstract]. American College of Clinical Pharmacology (ACCP) Annual Meeting.
  17. Enioutina EY, Wilkes J, Olson J, Thorell EA, Pavia AT, Sherwin CM, Balch AH (2017). IVIG patterns among Pediatric patients with neoplasms admitted to U.S. Pediatric hospitals [Abstract]. American College of Clinical Pharmacology (ACCP) Annual Meeting.
  18. Rower JE, Stockmann C, Molina KM, Sherwin CM (2017). Predicting Future Calcineurin Inhibitor Concentrations in Pediatric Transplant Recipients to Reduce Drug Monitoring Burden [Abstract]. American College of Clinical Pharmacology (ACCP) Annual Meeting.
  19. Illamola SM, Young V, Job KM, Balch AH, Varner MW, Sherwin CM (2017). Clinical management of antidepressants during pregnancy [Abstract]. American College of Clinical Pharmacology (ACCP) Annual Meeting.
  20. Muhari-Stark E, Chen X, Sherwin CM, Wang Y, Wang J, Yao L (2017). Association of meropenem clearance, covariates and estimated glomerular filtration rate in neonates [Abstract]. American College of Clinical Pharmacology (ACCP) Annual Meeting.
  21. Tak CR, Biltaji E, Kohlmann W, Maese L, Sherwin CM, Brixner D, Schiffman J (2017). Cost-effectiveness of an early cancer surveillance strategy for patients with Li-Fraumeni Syndrome [Abstract]. ISPOR 22nd Annual International, Boston, MA.
  22. Rattler TB Constance J, Sherwin CM (2016). Polypharmacy Among Hospitalized Pediatric Patients with Type 1 Diabetes Mellitus [Abstract]. Society for Advancement of Chicanos/Hispanics and Native Americans in Science (SACNAS).
  23. Ford TA, Constance JE, Sherwin CM (2016). Type 1 Diabetes And The Risk Of Kidney Dysfunction Among Children Receiving Intravenous Antibiotics [Abstract]. Pediatric Academic Societies (PAS) Annual Meeting 2016, Baltimore, MA.
  24. Balch A, Yu T, Constance JE, Sherbotie J, Rower J, Korgenski EK, Sherwin CM (2016). Is Generic Tacrolimus Bioequivalent In Patients? [Abstract]. American College of Clinical Pharmacology (ACCP) Annual Meeting.
  25. Caston R, Constance JE, Balch A, Korgenski EK, Sherwin CM (2016). Vancomycin-associated nephrotoxicity among Pediatric patients with hematologic malignancy [Abstract]. American College of Clinical Pharmacology (ACCP) Annual Meeting.
  26. Liu X, Tak C, Sherwin CM, Shakib JH (2016). Population modeling of the influence of maternal influenza vaccination on infant immunity [Abstract]. American Association of Pharmaceutical Scientists (AAPS).
  27. Molina K, Rower J, Stockmann C, Sherwin CM (2016). Predicting Tacrolimus Concentrations in Heart Transplant Recipients Using Population Pharmacokinetic Models [Abstract]. American Heart Association, New Orleans, LA.
  28. Constance JE, Linakis MW, Stockmann C, Roberts JK, Sherwin CM, Spigarelli MG (2015). Inpatient polypharmacy among children with leukemia or lymphoma receiving IV antibiotic therapy within the first year from diagnosis [Abstract]. Translating Cancer Epidemiology, Huntsman Cancer Institute, Salt Lake City, UT.
  29. Constance JE, Rower J, Stockmann C, Balch A, Sherwin CM, Spigarelli MG (2015). IV anti-infective use in pediatric patients with cancer [Abstract]. Translating Cancer Epidemiology, Huntsman Cancer Institute, Salt Lake City, UT.
  30. Linakis MW, Sherwin CM, Roberts JK, Spigarelli MG, Wilkins DG (2015). Population pharmacokinetics of nicotine delivered from a transdermal matrix patch [Abstract]. American Association of Pharmaceutical Scientists (AAPS), 2015, Orlando, FL.
  31. Yu T, Liu X, Balch AH, Molina KM, Constance JE, Prevedel JA, Korgenski EK, Spigarelli MG, Sherwin CM (2015). Population pharmacokinetics of tacrolimus in pediatric heart transplant patients [Abstract]. American Association of Pharmaceutical Scientists (AAPS), 2015, Orlando, FL.
  32. Liu X, Yu T, Balch AH, Sherbotie J, Korgenski EK, Spigarelli MG, Sherwin CM (2015). Population Pharmacokinetics of Tacrolimus in Pediatric Patients with Kidney Transplant [Abstract]. American Association of Pharmaceutical Scientists (AAPS), 2015, Orlando, FL.
  33. Constance JE, Linakis MW, Balch AH, Sherwin CM, Spigarelli MG (2015). Inpatient polypharmacy among children with leukemia or lymphoma receiving IV antibiotic therapy within the first year from diagnosis [Abstract]. IATDMCT Congress 2015, Rotterdam, The Netherlands.
  34. Balch AH, Constance JE, Sherwin CM, Spigarelli MG (2015). A Retrospective Study of Kidney Injury vs Vancomycin Use by Age [Abstract]. American College of Clinical Pharmacology (ACCP), 2015, San Francisco, CA.
  35. Constance JE, Ward RM, Sherwin CM, Korgenski K, Spigarelli MG (2015). Nonsteroidal anti-inflammatory drug-associated nephrotoxicity among neonates diagnosed with patent ductus arteriosus [Abstract]. American College of Clinical Pharmacology (ACCP), 2015, San Francisco, CA.
  36. Balch A, Green T, Hansen C, Sherwin CM (2015). Practical Issues in Calculating Sample Size for Ordinal Data with Repeated Measures [Abstract]. Joint Statistical Meeting (JSM) 2015, Seattle, WA.
  37. Schiffman JD, Kirchhoff AC, Spigarelli MG, Kaul S, Smits-Seemann R, Sherwin CM, Constance JE, Brenna Eldridge B, Fluchel M, Christenson CP, Garfield K, Mason CC, Korgenski EK Knackstedt ED, Blaschke A, Raetz EA, Lemons RS, Clark EB (5/29/2015). Building a comprehensive, value-based resource for childhood cancer in Utah [Abstract]. American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, Illinois, 2015.
  38. Enioutina EY, Constance JE, Balch AH, Sherwin CM, Spigarelli MG (2015). Vaccination patterns among pediatric cancer patients treated with vancomycin [Abstract]. American Society for Clinical Pharmacology and Therapeutics, ASCPT 2015.
  39. Balch AH, Constance JE, Sherwin CM, Spigarelli MG (2015). The Effect of tyrosine kinase inhibitors on pediatric growth [Abstract]. American Society for Clinical Pharmacology and Therapeutics, ASCPT 2015.
  40. Bhongsatiern J, Stockmann C, Yu T, Moorthy G, Constance JE, Spigarelli MG, Desai PB, Sherwin CM (2015). Renal function descriptors in neonates: Which creatinine-based equation best describes vancomycin clearance? [Abstract]. American Society for Clinical Pharmacology and Therapeutics, ASCPT 2015.
  41. Constance JE, Balch AH, Enioutina EY, Stockmann C, Linakis M, Sherwin CM, Spigarelli MG (2015). Polypharmacy among hospitalized pediatric cancer patients [Abstract]. American Society for Clinical Pharmacology and Therapeutics, ASCPT 2015.
  42. Stockmann C, Hersh AL, Sherwin CM, Spigarelli MG, Frymoyer A (2015). Targeting Vancomycin AUC in Neonates - A Model Based Bayesian Approach for Personalized Therapeutic Drug Monitoring [Abstract]. American Society for Clinical Pharmacology and Therapeutics, ASCPT 2015.
  43. Prevedel JA, Constance JE, Sherwin CM, Spigarelli MG (2015). Patterns of Tacrolimus Use in Pediatric Heart Transplant Recipient [Abstract]. Pediatric Academic Societies (PAS) Annual Meeting, 2015, San Diego, CA.
  44. Campbell SC, Johnson-Davis KL, Linakis MW, McMillin GA, Sherwin CM, Spigarelli MG (2014). Evaluating the Relationship of Age and Thiopurine Metabolites in Pediatrics [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Diego, CA.
  45. Linakis MW, Stockmann C, Campbell SC, Williams RV, Burch PT, Lambert LM, Sherwin CM, Reilly CA, Spigarelli MG (2014). A Novel Sensitive and Specific Liquid Chromatography-Tandem Mass Spectrometry (LC-MS-MS) Method for the Quantification of Oxandrolone in Human Plasma [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Diego, CA.
  46. Sneddon JR, Campbell SC, Balch AH, Sherwin CM, Spigarelli MG (2014). Trends of KRAS Pharmacogenomic Testing for Cetuximab and Panitumumab [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Diego, CA.
  47. Constance JE, Sherwin CM, Korgenski EK Spigarelli MG (2014). Intravenous meropenem use among pediatric patients with and without cancer [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Diego, CA.
  48. Yu T, Stockmann C, Constance JE, Korgenski EK, Spigarelli MG, Sherwin CM (2014). Population Pharmacokinetics and Dosing Regimen Optimization of Intravenous Vancomycin in Infants [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Diego, CA.
  49. Clements N, Constance JE, Yu T, Campbell SC, Linakis M, Sherwin CM, Spigarelli MG (2014). Therapeutic drug monitoring and target vancomycin attainment among pediatric patients undergoing hemodialysis [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Diego, CA.
  50. Linakis MW, Campbell SC, Stockmann C, Johnson-Davis KL, McMillin GA, Balch AH, Sherwin CM, Spigarelli MG (2014). Frequency of Thiopurine Metabolite Tests with Clinically-Important Results Requiring Modifications to Therapy [Abstract]. American Academy of Pediatrics (AAP) National Conference and Exhibition, San Diego, CA.
  51. Balch AH, Constance JE, Sherwin CM, Spigarelli MG (2014). Pediatric Cancer Patients Receiving Gentamicin and Vancomycin Receive Higher Doses and More Combination Therapy [Abstract]. American Academy of Pediatrics (AAP) National Conference and Exhibition, San Diego, CA.
  52. Baserga M, Beachy J, Yoder BA, Ward RM, Roberts JK, Sherwin CM, Spigarelli MG, DiGeronimo R, Ohls R, Walsh W, Mayock D, Juul SE, Christensen R (2014). DANCE (Darbe Administration in Newborns Undergoing Cooling for Encephalopathy: Safety and Pharmacokinetic Trial. American Academy of Pediatrics [Abstract]. American Academy of Pediatrics (AAP) National Conference and Exhibition, San Diego, CA.
  53. Yu T, Campbell SC, Stockmann C, Clark EAS, Varner MW, Spigarelli MG, Sherwin CM (2014). Pharmacokinetic Changes of Caffeine during Pregnancy and Simulation of Pregnant Population [Abstract]. American Conference on Pharmacometrics (ACoP), Las Vegas, NV.
  54. Cook SF, Sherwin CM, Williams EF, Roberts JK, King AD, Deutsch N, Samiee-Zafarghandy S, Mankala S, Wilkins DG, van den Anker JN (2014). Population pharmacokinetics of intravenous acetaminophen in preterm and term neonates [Abstract]. American Conference on Pharmacometrics (ACoP), Las Vegas, NV.
  55. Stockmann C, Sherwin CM, Spigarelli MG (2014). zscore – An R Package for Deriving Weight and Height for Age Z Scores and Exact Percentiles from Birth to 20 Years of Age [Abstract]. American Conference on Pharmacometrics (ACoP), Las Vegas, NV.
  56. Bhongsatiern J, Sherwin CM, Yu T, Stockmann C, Allegaert K, Knibbe CAJ, Reith DM, Desai PB, Spigarelli MG (2014). Development of Vancomycin Dosing Recommendations in Preterm and Term Neonates using Population Pharmacokinetic Modeling and Simulation [Abstract]. American Conference on Pharmacometrics (ACoP), Las Vegas, NV.
  57. Roberts JK, Ward RM, Beachy J, Baserga M, Spigarelli MG, Sherwin CM (2014). Population pharmacokinetics of darbepoetin alfa for the treatment of neonatal hypoxic-ischemic encephalopathy [Abstract]. American Conference on Pharmacometrics (ACoP), Las Vegas, NV.
  58. Constance JE, Balch AH, Sherwin CM, Spigarelli MG (2014). Patterns of Gentamicin Use Among Pediatric Cancer Patients [Abstract]. American College of Clinical Pharmacology (ACCP) Annual Meeting.
  59. Linakis MW, Campbell SC, Stockmann C, Johnson-Davis KL, McMillin GA, Sherwin CM, Spigarelli MG (2014). Regional Differences in Thiopurine Methyltransferase Activity [Abstract]. American College of Clinical Pharmacology (ACCP) Annual Meeting.
  60. Han H, Constance JE, Sherwin CM, Korgenski EK, Spigarelli MG (2014). Evaluation of disparities in achieving therapeutic recommendations among pediatric patients receiving gentamicin [Abstract]. American College of Clinical Pharmacology (ACCP) Annual Meeting.
  61. De Cock RFW, Allegaert K, Brussee J, Sherwin CM, Mulla H, de Hoog M, van den Anker JN, Danhof M, Knibbe CAJ (2014). Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration [Abstract]. PAGE 23. Population Approach Group in Europe. Abstr 3167. www.page-meeting.org/?abstract=3167], Alicante, Spain.
  62. Yu T, Balch AH, Spigarelli MG, Sherwin CM (2014). Population Pharmacokinetics/Pharmacodynamics of Intravenous Vancomycin in Adolescent Patients [Abstract]. Pediatric Academic Societies & Asian Society for Pediatric Research Joint Meeting, Vancouver, Canada.
  63. Campbell SC, Johnson-Davis K, Linakis MW, Roberts JK, McMillin GA, Sherwin CM, Spigarelli MG (2014). Evaluating the Relationship of Age and Thiopurine Methyltransferase Activity [Abstract]. Pediatric Academic Societies & Asian Society for Pediatric Research Joint Meeting, Vancouver, Canada.
  64. Campbell SC, Johnson-Davis K, McMillin GA, Sherwin CM, Spigarelli MG (2014). Trends of Pediatric and Adolescent TPMT Pharmacogenomic Testing [Abstract]. Pediatric Academic Societies & Asian Society for Pediatric Research Joint Meeting, Vancouver, Canada.
  65. Stockmann C, Hersh AL, Pavia AT, Byington CL, Blaschke AJ, Sherwin CM, Spigarelli MG, Ampofo K (2014). National Trends in Pediatric Pyogenic Arthritis and Osteomyelitis, 1997 – 2009 [Abstract]. Pediatric Academic Societies & Asian Society for Pediatric Research Joint Meeting, Vancouver, Canada.
  66. Constance JE, Campbell SC, Stockmann C, Balch AH, Korgenski EK, Sherwin CM, Spigarelli MG (2014). Incidence of acute kidney injury among vancomycin-treated children with hematologic malignancies [Abstract]. Pediatric Pharmacogenomics and Personalized Medicine Conference, Kansas City, MO.
  67. Roberts JK, Sherwin CM, Beachy J, Ward RM, Baserga M, Spigarelli MG (2014). Pharmacokinetics of Darbepoetin Alfa in the Treatment of Hypoxic-Ischemic Encephalopathy [Abstract]. Pediatric Pharmacogenomics and Personalized Medicine Conference, Kansas City, MO, Encore.
  68. Schoen K, Constance J, Sherwin CM, Ward R, Spigarelli MG (2013). Determination of Vancomycin Induced Nephrotoxicity in Neonates with Patent Ductus Arteriosus [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Antonio, TX.
  69. Yu T, Sherwin CM, Stockmann C, Spigarelli MG (2013). Evolution of Vancomycin Clinical Trials and Development of New Antibiotic Therapies for Resistant Gram-Positive Bacterial Infections in the United States from 1999 to 2012 [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Antonio, TX.
  70. Firth SD, Yakub SY, Sherwin CM, Korgenski K, Constance JE, Stockmann C, Balch A, Spigarelli MG (2013). Therapeutic Monitoring of Vancomycin in Children: Is There a Cost to Non-adherence of Guidelines? [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Antonio, TX.
  71. Campbell SC, Linakis MW, Tak CR, McMillin G, Sherwin CM, Spigarelli MG (2013). Clinical Utilization of Pharmacogenomic Testing: What is it for Drugs with Strong Recommendations? [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Antonio, TX.
  72. Constance JE, Balch A, Campbell SC, Stockmann C, Sherwin CM, Spigarelli MG (2013). Nephrotoxicity associated with vancomycin use in a pediatric population [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Antonio, TX.
  73. Yu T, Stockmann C, Sherwin CM, Olson J, Healy D, Spigarelli MG (2013). Determination of an Optimal Amikacin Dosing Regimen for Pediatric Burn Patients [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Antonio, TX.
  74. Bhongsatiern J, Sherwin CM, Stockmann C, Yu T, Reith DM, Desai PB Spigarelli MG (2013). Use of Monte Carlo Simulation to Evaluate Vancomycin Dosing Regimens in Neonates [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Antonio, TX.
  75. Firth SD, Yakub SY, Sherwin CM, Korgenski K, Constance JE, Stockmann C, Balch A, Spigarelli MG (2013). Assessment of Guideline Adherence for Pediatric Vancomycin Use [Abstract]. American Association of Pharmaceutical Scientists (AAPS), San Antonio, TX.
  76. Spigarelli MG, Healy D, Buterbaugh W, Gottschlich MM, Kagan R, Sherwin CM (2013). Rapid Repeat Dosing of Zolpidem - Apparent Kinetic Change Between Doses [Abstract]. PAGE 22. Population Approach Group in Europe. Abstr 2943. www.page-meeting.org/?abstract=2943, Glasgow, Scotland.
  77. Sherwin CM, Jones B, Leeder JS, Neville KA, Kearns GL, Spigarelli MG (2013). Dense Data - Methods to Handle Massive Data Sets without Compromise [Abstract]. PAGE 22. Population Approach Group in Europe. Abstr 2942. www.page-meeting.org/?abstract=2942. Glasgow, Scotland.
  78. Sherwin CM, Constance JE, Spigarelli M G (2013). Comparison of Serum Vancomycin Concentrations in a Paediatric Population pre- and post- 2009 IDSA Guideline Recommendations. [Abstract]. In: 14th Biannual Congress of the European Society for Developmental Perinataland Pediatric Pharmacology (ESDPPP). Salzburg, Austria, 04.-07.06.2013. Düsseldorf: German Medical Science GMS Publishing House;2013. DocPP55.DOI: 10.3205/13esdppp82, URN: urn:nbn:de:0183-13esdppp823.
  79. Sherwin CM, Stockmann C, Healy D, Buterbaugh W, Gottschlich MM, Spigarelli MG, Kagan R (2013). Population Pharmacokinetics of Zolpidem among Children with Severe Burn Injuries. [Abstract]. In: 14th Biannual Congress of the European Society for Developmental Perinatal and Pediatric Pharmacology (ESDPPP). Salzburg, Austria, 04.-07.06.2013. Düsseldorf: German Medical Science GMS Publishing House; 2013.DocFP13.DOI: 10.3205/13esdppp13, URN: urn:nbn:de:0183-13esdppp133.
  80. Doll E, Wilkes J, Sherwin CM, Srivastava R, Faix R, Spigarelli MG, Clark EAS, Bonkowsky J (2013). Neonatal Magnesium Levels Correlate with Improved Neurological Outcomes in Premature Infants [Abstract]. Pediatric Academic Societies (PAS) Annual Meeting, Washington DC.
  81. Green AA, Campbell SC, Sherwin CM, McMillin GA, Spigarelli MG (2013). Pharmacogenomic Testing Trends in Pediatric Patients [Abstract]. Pediatric Academic Societies (PAS) Annual Meeting, Washington DC.
  82. Stockmann C, Sherwin CM, Campbell SC, Linakis M, Constance J, Balch A, Spigarelli MG (2013). Characteristics of Maternal-Fetal Pharmacology Studies Registered in the United States through ClinicalTrials.gov [Abstract]. Pediatric Academic Societies (PAS) Annual Meeting, Washington DC.
  83. Balch A, Stockmann C, Constance J, Yu T, Campbell SC, Sherwin CM, Spigarelli MG (2013). Therapeutic Monitoring of Vancomycin Concentrations and Healthcare Provider Response to High and Low Troughs. [Abstract]. Pediatric Academic Societies (PAS) Annual Meeting, Washington DC.
  84. Constance J, Durbano D, Campbell SC, Sherwin CM, Balch A, Spigarelli MG (2013). Nephrotoxicity Associated with Vancomycin Use in a Neonatal Population [Abstract]. Pediatric Academic Societies (PAS) Annual Meeting, Washington DC.
  85. Linakis M, Constance J, Bailey S, Stockmann C, Campbell SC, Balch A, Sherwin CM, Spigarelli MG (2013). Role of MRSA and Coagulase-Negative Staphylococcus Bacteremia in the Increasing Use of Vancomycin.http://www.healio.com/pediatrics/emerging-diseases/news/online/%7B323e9862-f13f-4310-bf57-13da6a267ab1%7D/vancomycin-use-increased-despite-modest-increase-in-mrsa-and-coagulase-negative-staphylococcus [Abstract]. Pediatric Academic Societies (PAS) Annual Meeting, Washington DC.
  86. Yakub SY, Campbell SC, Sherwin CM, Constance J, Balch A, Spigarelli MG (2013). Prolonged Vancomycin Use in a Pediatric Population [Abstract]. Pediatric Academic Societies (PAS) Annual Meeting Washington DC.
  87. Campbell SC, McMillin GA, Sherwin CM, Spigarelli, MG (2013). Thiopurine Methyltransferase Pharmacogenomic Test Utilication in Pediatrics [Abstract]. Pediatric Academic Societies (PAS) Annual Meeting, Washington DC.
  88. Sherwin CM, Wead S, Stockmann CR, Healy D, Spigarelli MG, Neely, A (2013). Amikacin Population Pharmacokinetics Associated with Pediatric Burn Patients [Abstract]. Pediatric Academic Societies (PAS) Annual Meeting, Washington DC.
  89. Campbell SC, McMillin GA, Sherwin CM, Spigarelli MG (2013). Pharmacogenomic Testing Trends in Adolescents [Abstract]. Pediatric Pharmacogenomics and Personalized Medicine Conference, Kansa City, MO.
  90. Campbell SC, Sherwin CM, McMillin GA, Spigarelli M (2012). Understanding the Use and Trends of Pharmacogenomic Testing [Abstract]. American Association of Pharmaceutical Scientists (AAPS), Chicago, IL.
  91. Dowse B, Campbell S, Sherwin CM, Spigarelli M (2012). Trends in use and monitoring of vancomyin in pediatric patients. [Abstract]. American College of Clinical Pharmacology (ACCP) Annual Meeting.
  92. Burch P, Minich LL, Spigarelli M, Lambert L, Sherwin CM, Williams RV (2012). Use of Oxandrolone to Promote Growth In Neonates with Complex Congenital Heart Disease: An Open-Label Pilot Trial. [Abstract]. American Academy of Pediatrics (AAP) National Conference and Exhibition.
  93. De Cock RFW, Allegaert K, Sherwin CM, de Hoog M, van den Anker, JN, Danhof M, Knibbe CAJ (2011). Maturation of GFR in preterm and term neonates reflected by clearance of different antibiotics [Abstract]. PAGE 20. Population Approach Group in Europe. Abstr 2096. www.page-meeting.org/?abstract=2096. Athens, Greece.
  94. Saldana SN, Sherwin CM, Kuijvenhovem M, Aman, M, Vinks AA (2010). Population Pharmacokinetics of Risperidone Using Sparse and D-Optimal Sampling in Children and Adolescents. [Abstract]. Pediatric Pharmacogenomics and Personalized Medicine Conference, Encore.
  95. Reith DM, Owens K, Svahn S, Boradbent RS, Medlicott NJ, Sherwin CM (2009). Pharmacokinetic Pharmacodynamic study of hearing impairment in neonates treated with aminoglycosides using a logistic regression model [Abstract]. Basic & Clinical Pharmacology & Toxicology, 105(Suppl 1), 131.
  96. Owen K, Sherwin CM, Medlicott NJ, Reith DM (2008). Evaluating Gentamicin and Ototoxicity in Neonates to Optimize Development of a New Dosing Regimen [Abstract]. PAGANZ 08; Abstract 1077, Population Approach Group of Autralian and New Zealand, Dunedin, New Zealand.
  97. Owens K, Sherwin CM, Reith DM, Medlicott NJ (2008). Evaluating Gentamicin and Ototoxicity in Neonates to Optimize Development of a New Dosing Regimen [Abstract]. New Zealand Medical Journal, 121(1274).
  98. Owens K, Sherwin CM, Medlicott NJ, Reith DM (2008). Investigation of Hearing Impairment in Neonates Treated with Aminoglycosides [Abstract]. Otago Medical Research Foundation Meeting, Summer Studentships, Dunnedin; New Zealand.
  99. McCaffrey F, Sherwin CM, Broadbent R, Reith DM, Medlicott NJ (2008). What's in Delivery? [Abstract]. Proceedings of the New Zealand Neonatal Conference; Hamilton, New Zealand.
  100. Broadbent R, Sherwin CM, Kostan E, Medlicott NJ, Reith DM (2008). The Effect Upon Volume of Distribution of Intravenous Volume Expanders Delivered to Neonates Treated with Gentamicin for Suspected Sepsis. Proceedings of the 2nd Congress of the European Academy of Pediatrics; Nice, France [Abstract]. Archives of Disease in Childhood, 93(Supplement 2), espnic31.
  101. Sherwin CM, Medlicott NJ, Broadbent RS, Reith DM (2008). Simulation and development of a netilmicin extended dosing regimen for extremely premature neonates [Abstract]. PAGE 17. Population Approach Group in Europe. Abstr 1241. www.page-meeting.org/?abstract=1241. Marseille, France.
  102. Sherwin CM, Svahn S, Medlicott NJ, Broadbent RS, Reith DM (2008). Pharmacodynamic analysis of hearing impaired neonates treated with amikacin. [Abstract]. American Conference on Pharmacometrics (ACoP), Tucson, AZ.
  103. Sherwin CM, Svahn S, Van der Linden AJ, Medlicott NJ, Broadbent RS, Reith DM (2008). Simulation of an optimal pharmacokinetic and pharmacodynamic amikacin dosing regimen for neonates. [Abstract]. PAGANZ 08 ; Population Approach Group of Autralian and New Zealand, Dunedin, New Zealand.
  104. Broadbent R, Sherwin CM, Young S, Worth J, McCaffrey F, Medlicott NJ, et al (2007). Utility of IL-12 and IL-10 in Comparison with Other Cytokines and Acute Phase Reactants in teh Initial workup of Suspected Neonatal Sepsis [Abstract]. British Pediatric Society; Isle of Man, UK.
  105. Broadbent R, Sherwin CM, Young S, Worth J, McCaffrey F, Medlicott NJ, et al (2007). Utility of IL-12 and IL-10 in Comparison with Other Cytokines and Acute Phase Reactants on Day Three of Suspected Neonatal Sepsis [Abstract]. World Congress of Perinatology, Florence, Italy.
  106. Sherwin CM, Svahn S, Van der Linden AJ, Medlicott NJ, Broadbent RS, Reith DM (2007). A Pharmacokinetic/Pharmacodynamic Model to Determine Optimal Dosing Targets for Amikacin in Neonatal Sepisis [Abstract]. PAGE 16. Population Approach Group in Europe. Abstract 1134, www.page-meeting.org/?abstract=1134. Copenhagen, Denmark.
  107. Sherwin CM, Kostan E, Medlicott NJ, Broadbent RS, Reith DM (2007). The Effect Upon V of IV Volume Expanders Delivered to Neonates Treated with Gentamicin for Suspected Sepsis [Abstract]. Australasian Society of Clinical and Experimental Pharmacology and Toxicology, Auckland, New Zealand.
  108. Sherwin CM, Broadbent RS, Reith DM (2006). A Pilot Study of Cytokines as Indicators of Pharmacokinetic Change for Gentamicin in Septic Neonates [Abstract]. PAGANZ 06, Population Approach Group of Autralian and New Zealand, Auckland, New Zealand.
  109. Sherwin CM, Svahn S, Medlicott NJ, Broadbent RS and Reith DM (2006). Netilmicin to Amikacin in Neonates...Was the Change Good [Abstract]. Australasian Society fo Clinical and Experiemental Pharmacologist, Auckland, New Zealand.
  110. Reith DM, Sherwin CM, Svahn S, Medlicott NJ, Broadbent R (2006). Netilmicin to Amikacin in Neonates...Was the Change Good? [Abstract]. Annual Meeting of the South Island Neonatal Group, Christchurch, New Zealand.
  111. Sherwin CM, Svahn S, Medlicott NJ, Broadbent RS, Reith DM (2006). Population pharmacokinetics of amikacin in extremely low birth weight to term neonates. [Abstract]. American Association of Pharmaceutical Scientists, San Antonio, TX.
  112. Sherwin CM, Broadbent RS and Reith DM (2005). Evaluation of the pharmacokinetics of netilmicin in neonates with suspected or proven sepsis [Abstract]. Proceedings of the joint conference of the Australasian Society of Clinical and Experimental Pharmacology and Toxicology and the Australian Pharmaceutical Science Association.

Other

  1. Rahimi R, Hashemi Rafsanjani SMR, Heidari-Soureshjani S, Sherwin CM, Kasiri K (2024). The Association between Use of Renin-Angiotensin-Aldosterone System Inhibitors and the Risk and Mortality of Pancreatic Cancer: A Systematic Review and Meta-Analysis. Curr Rev Clin Exp Pharmacol. Netherlands. (Read full article)
  2. Darvishi M, Amiri MM, Heidari-Soureshjani S, Sherwin CM, Mardani-Nafchi H (2023). The Association between Statins Intake and Risk of Post Stroke Pneumonia: A Systematic Review and Meta-analysis. Curr Rev Clin Exp Pharmacol. Netherlands. (Read full article)
  3. Anbari K, Amiri MM, Heidari-Soureshjani S, Sherwin CM, Kasiri K (2023). A Systematic Review and Meta-analysis on the Role of Statins in the Prevention of Mortality Following Pancreatic Cancer. Anticancer Agents Med Chem. Netherlands. (Read full article)
  4. Smit C, Goulooze SC, Brggemann RJM, Sherwin CM, Knibbe CAJ (2021). Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1-18 Years. AAPS J (23(3), p. 53). United States. (Read full article)
  5. Maharaj AR, Wu H, Zimmerman KO, Autmizguine J, Kalra R, Al-Uzri A, Sherwin CMT, Goldstein SL, Watt K, Erinjeri J, Payne EH, Cohen-Wolkowiez M, Hornik CP (2020). Population pharmacokinetics of olanzapine in children. Br J Clin Pharmacol (87(2), pp. 542-554). England. (Read full article)
  6. Zhang Y, Sherwin CM, Gonzalez D, Zhang Q, Khurana M, Fisher J, Burckart GJ, Wang Y, Yao LP, Ganley CJ, Wang J (2020). Creatinine-Based Renal Function Assessment in Pediatric Drug Development: An Analysis Using Clinical Data for Renally Eliminated Drugs. Clin Pharmacol Ther (109(1), pp. 263-269). United States. (Read full article)

Video/Film/CD/Web/Podcast

  1. Sherwin CM, Craig D, Yellepeddi V, Rosenthal L, Morris ME (2018). 9 Times Ibuprofen Won’t Work—and Could Be Dangerous by Joanna Chen [Web]. Reader’s Digest. Available: https://www.rd.com/health/wellness/times-ibuprofen-wont-work-and-could-be-dangerous/.
  2. Biltaji E, Biskupiak J, Sherwin CM, McMillin G, Brixner D (2018). The Value of Using Pharmacogenetic Risk Scores in Routine Practice [Web]. AMCP Managed Care & Specialty Pharmacy. Available: http://amcp2018.amcp.org/daily-report/the-value-of-using-pharmacogenetic-risk-scores-in-routine-practice/.
  3. Davis J, Rousseau R, Sherwin CM, Laughon M (2017). Here's how to make traditional medicines safer for newborns [Web]. Megan Scudellari, STAT. Available: http://www.businessinsider.com/make-traditional-medicines-safer-for-newborns-2017-1.
  4. Sherwin CM (2017). Giving newborns medicine is a dangerous guessing game. Can we make it safer? [Web]. Megan Scudellari, STATNews. Available: https://www.statnews.com/2017/01/03/neonatal-drugs-unapproved/.
  5. Ward RM, Sherwin CM (2017). Making Medications Safer for Newborns [Web]. London: sciencenewsroom@wiley.com. Available: http://www.wiley.com/WileyCDA/PressRelease/pressReleaseId-128648.html.